EP4048696A1 - Molécules de liaison à l'antigène anti-idiotypiques et procédés d'utilisation associés - Google Patents

Molécules de liaison à l'antigène anti-idiotypiques et procédés d'utilisation associés

Info

Publication number
EP4048696A1
EP4048696A1 EP20817103.3A EP20817103A EP4048696A1 EP 4048696 A1 EP4048696 A1 EP 4048696A1 EP 20817103 A EP20817103 A EP 20817103A EP 4048696 A1 EP4048696 A1 EP 4048696A1
Authority
EP
European Patent Office
Prior art keywords
binding molecule
seq
amino acid
acid sequence
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20817103.3A
Other languages
German (de)
English (en)
Inventor
Stuart SIEVERS
Jed J.W. Wiltzius
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kite Pharma Inc
Original Assignee
Kite Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kite Pharma Inc filed Critical Kite Pharma Inc
Publication of EP4048696A1 publication Critical patent/EP4048696A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Definitions

  • This disclosure relates to antigen binding molecules as well as molecules comprising these sequences and cells presenting such molecules, polynucleotides encoding such antigen binding molecules, as well as humanized forms of the antigen binding molecules; methods of using the antigen binding molecules are also disclosed.
  • This disclosure relates to antigen binding molecules as well as molecules comprising these sequences and cells presenting such molecules, polynucleotides encoding such antigen binding molecules, as well as humanized forms of the antigen binding molecules; methods of using the antigen binding molecules are also disclosed.
  • Antigen binding molecules including antibodies, and fragments such as Fabs,
  • Anti-idiotypic antibodies are a subset of antibodies, and are antibodies raised against immunizing antibodies. These anti-idiotypic antibodies demonstrated specific binding against the idiotopes (unique antigenic determinants on the surface of the antibodies) of the immunizing antibodies.
  • Anti-idiotypic antibodies may be generally classified into three distinct groups: (1) antibodies are those that recognize idiotopes distinct from the antigen binding site (ABS) on immunizing antibodies; (2) antibodies that recognize epitopes within the ABS and mimic the structure, and forming the so-called “internal image,” of the nominal antigen; and (3) antibodies that recognize epitopes within the ABS without the structural resemblance of the nominal antigen (see, e.g., Pan etal, (1995) FASEB ,79:43-49).
  • ABS antigen binding site
  • CLL-1 C-type lectin like molecule- 1
  • the present disclosure provides an isolated antigen binding molecule that specifically binds a molecule comprising a CLL-1 binding molecule.
  • the CLL-1 binding molecule binds human CLL-1.
  • the isolated antigen binding molecule is humanized.
  • the antigen binding molecule is selected from the group consisting of an antibody, an scFv, a Fab, a Fab’, a Fv, a F(ab’)2, a dAb, a human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a polyclonal antibody, a recombinant antibody, an IgE antibody, an IgD antibody, an IgM antibody, an IgGl antibody, an IgGl antibody having at least one mutation in the hinge region, an IgG2 antibody an IgG2 antibody having at least one mutation in the hinge region, an IgG3 antibody, an IgG3 antibody having at least one mutation in the hinge region, an IgG4 antibody, an IgG4 antibody having at least one mutation in the hinge region, an antibody comprising at least one non-naturally occurring amino acid, and any combination thereof.
  • the antigen binding molecule comprises a heavy chain
  • the HC comprises a heavy chain variable region (VH) sequence selected from the group consisting of SEQ ID NOs: 1-7 and 15-21.
  • VH heavy chain variable region
  • variable region (VH) and comprises one or more of
  • the antigen binding molecule comprises a heavy chain
  • the antigen binding molecule comprises a heavy chain
  • the antigen binding molecule comprises a heavy chain
  • the heavy chain comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3, each CDR comprising an amino acid sequence shown in Table C and D.
  • the antigen binding molecule comprises a VH amino acid sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NOs: 15-21.
  • the antigen binding molecule comprises a light chain
  • the LC comprises a light chain variable region (VL) sequence selected from the group consisting of SEQ ID NOs: 22-28.
  • VL light chain variable region
  • variable region (VL) and comprises one or more of
  • the antigen binding molecule comprises a light chain CDR1 selected from the group consisting of SEQ ID NOs: 29, 32, 35, 37, 40, 43, and 46. In some embodiments, the antigen binding molecule comprises a light chain CDR2 selected from the group consisting of SEQ ID NOs: 30, 33, 38, 44, and 47. In some embodiments, the antigen binding molecule comprises a light chain CDR3 selected from the group consisting of SEQ ID NOs: 31, 34, 36, 39, 42, 45, and 48.
  • the light chain comprises a light chain CDR1, a light chain CDR2, and a light chain CDR3, each CDR comprising an amino acid sequence shown in one of Table C or D.
  • the antigen binding molecule comprises a VL amino acid sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a VL comprising SEQ ID NOs: 22-28.
  • the antigen binding molecule comprises: (a) a
  • VH comprising the amino acid sequence of SEQ ID NO: 15; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 22.
  • the antigen binding molecule comprises:
  • VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 49;
  • VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 29;
  • VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 30;
  • the antigen binding molecule comprises: (a) a VH comprising the amino acid sequence of SEQ ID NO: 16; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 23.
  • the antigen binding molecule comprises:
  • VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 52;
  • VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 32;
  • VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 33;
  • the antigen binding molecule comprises: (a) a VH comprising the amino acid sequence of SEQ ID NO: 17; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 24.
  • the antigen binding molecule comprises:
  • VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 55;
  • VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 35;
  • VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 33;
  • the antigen binding molecule comprises: (a) a VH comprising the amino acid sequence of SEQ ID NO: 18; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 25.
  • the antigen binding molecule comprises:
  • VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 58;
  • VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 37;
  • VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 38;
  • the antigen binding molecule comprises: (a) a VH comprising the amino acid sequence of SEQ ID NO: 19; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 26.
  • the antigen binding molecule comprises:
  • VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 40;
  • VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 30;
  • the antigen binding molecule comprises: (a) a VH comprising the amino acid sequence of SEQ ID NO: 20; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 27.
  • the antigen binding molecule comprises:
  • VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 64;
  • VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 43;
  • VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 44;
  • the antigen binding molecule comprises: (a) a VH comprising the amino acid sequence of SEQ ID NO: 21; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 28.
  • the antigen binding molecule comprises:
  • VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 67;
  • the antigen binding molecule further comprises a detectable label.
  • the detectable label is selected from the group consisting of a fluorescent label, a photochromic compound, a proteinaceous fluorescent label, a magnetic label, a radiolabel, and a hapten.
  • the fluorescent label is selected from the group consisting of an Atto dye, an Alexafluor dye, quantum dots, Hydroxycoumarin, Aminocouramin, Methoxycourmarin, Cascade Blue, Pacific Blue, Pacific Orange, Lucifer Yellow, NBD, R-Phycoerythrin (PE), PE-Cy5 conjugates, PE-Cy7 conjugates, Red 613, PerCP, TruRed, FluorX, Fluorescein, BODIPY-FL, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, TRITC, X-Rhodamine, Lissamine Rhocamine B, Texas Red, Allophycocyanin (APC), APC-Cy7 conjugates, Indo-1, Fluo-3, Fluo-4, DCFH, DHR, SNARF, GFP (Y66H mutation), GFP (Y66F mutation), EBFP, EBFP2, Azurite, GFPuv, T-Sapphire, Cerulean
  • the present disclosure provides a composition comprising the antigen binding molecule that specifically binds a molecule comprising a CLL-1 binding molecule described herein.
  • the present disclosure provides a polynucleotide encoding the heavy chain of an antigen binding molecule that specifically binds a molecule comprising a CLL-1 binding molecule described herein.
  • the present disclosure provides a polynucleotide encoding the light chain of an antigen binding molecule that specifically binds a molecule comprising a CLL-1 binding molecule described herein.
  • the present disclosure provides a vector comprising the polynucleotide encoding the heavy chain and/or the light chain of an antigen binding molecule described herein.
  • the present disclosure provides a cell comprising one or both of the vectors encoding the heavy chain and/or the light chain of an antigen binding molecule that specifically binds a molecule comprising a CLL-1 binding molecule described herein.
  • the cell comprises a cell selected from the group consisting of a CHO cell, a Sp2/0 cell, a rabbit cell and an E. coli cell.
  • the present disclosure provides a method of making an antigen binding molecule described herein, comprising incubating the cell comprising the vector encoding an antigen binding molecule that specifically binds a molecule comprising a CLL- 1 binding molecule under suitable conditions.
  • the present disclosure provides a method of administering a dose of a medicament to a subject, the dose comprising a preselected number of cells presenting a therapeutic molecule comprising a CLL-1 binding molecule, the method comprising: (a) providing a sample of known volume comprising a population comprising a known number of cells, which cells are known or suspected to be presenting a molecule comprising a CLL- 1 binding molecule; (b) providing an aliquot of the sample comprising a population of cells presenting a therapeutic molecule comprising a CLL-1 binding molecule; (c) providing an antigen binding molecule that specifically binds the a CLL-1 binding molecule, the antigen binding molecule further comprising a detectable label; (d) contacting the aliquot of (b) with the antigen binding molecule of (c) under conditions that permit the formation of a binding complex comprising a cell present in the sample and the antigen binding molecule; (e) determining the fraction of cells present in
  • the molecule comprising a CLL-1 binding molecule is a CAR.
  • the cell is an immune cell selected from the group consisting of CD8+ T cells, CD4+ T cells, tumor infiltrating lymphocytes (TILs), NK cells, TCR- expressing cells, dendritic cells, and NK-T cells.
  • the CAR further comprises a molecule, or a fragment thereof, selected from the group consisting of CD28, OX-40, 4-1BB/CD137, CD2, CD7, CD27, CD30, CD40, Programmed Death-1 (PD-1), inducible T cell co-stimulator (ICOS), lymphocyte function-associated antigen- 1 (LFA-1, CDl-la/CD18), CD3 gamma, CD3 delta, CD3 epsilon, CD3 zeta, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class 1 molecule, TNF receptor proteins, an Immunoglobulin protein, cytokine receptor, integrins, Signaling Lymphocytic Activation Molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, ICAM-1
  • the detectable label is selected from the group consisting of a fluorescent label, a photochromic compound, a proteinaceous fluorescent label, a magnetic label, a radiolabel, and a hapten.
  • the fluorescent label is selected from the group consisting of an Atto dye, an Alexafluor dye, quantum dots, Hydroxycoumarin, Aminocouramin, Methoxycourmarin, Cascade Blue, Pacific Blue, Pacific Orange, Lucifer Yellow, NBD, R-Phycoerythrin (PE), PE-Cy5 conjugates, PE-Cy7 conjugates, Red 613, PerCP, TruRed, FluorX, Fluorescein, BODIPY-FL, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, TRITC, X-Rhodamine, Lissamine Rhocamine B, Texas Red, Allophycocyanin (APC), APC-Cy7 conjugates, Indo-1, Fluo-3, Fluo-4, DCFH, DHR, SNARF, GFP (Y66H mutation), GFP (Y66F mutation), EBFP, EBFP2, Azurite, GFPuv, T-Sapphire, Cerulean
  • the immune cell is a T cell. In some embodiments, the
  • T cell is disposed in vitro. In some embodiments, the T cell is disposed in vivo. In some embodiments, the T cell is in one of blood, extracted tissue, tissue grown ex vivo, and cell culture media.
  • the T cell is an autologous T cell.
  • the T cell is an allogenic T cell.
  • the dose comprises l.OxlO 6 cells per kg.
  • the antigen binding molecule comprises an antigen binding molecule of described herein and humanized forms thereof.
  • the present disclosure provides a method of determining a number of cells presenting a molecule comprising a CLL-1 binding molecule in a sample, the method comprising: (a) providing a sample comprising cells known or suspected to be presenting a molecule comprising a CLL-1 binding molecule; (b) contacting the sample of (a) with an antigen binding molecule that specifically binds the molecule comprising a CLL- 1 binding molecule, the antigen binding molecule further comprising a detectable label, under conditions that permit the formation of a binding complex comprising a cell present in the sample and the antigen binding molecule; and (c) determining the number of cells present in a binding complex of (b) in the sample.
  • the molecule comprising a CLL-1 binding molecule is a CAR.
  • the cell is an immune cell selected from the group consisting of CD8+ T cells, CD4+ T cells, tumor infiltrating lymphocytes (TILs), NK cells, TCR- expressing cells, dendritic cells, and NK-T cells.
  • the CAR further comprises a molecule, or a fragment thereof, selected from the group consisting of CD28, OX-40, 4-1BB/CD137, CD2, CD7, CD27, CD30, CD40, Programmed Death-1 (PD-1), inducible T cell co-stimulator (ICOS), lymphocyte function-associated antigen- 1 (LFA-1, CDl-la/CD18), CD3 gamma, CD3 delta, CD3 epsilon, CD3 zeta, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class 1 molecule, TNF receptor proteins, an Immunoglobulin protein, cytokine receptor, integrins, Signaling Lymphocytic Activation Molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, ICAM-1
  • the detectable label is selected from the group consisting of a fluorescent label, a photochromic compound, a proteinaceous fluorescent label, a magnetic label, a radiolabel, and a hapten.
  • the fluorescent label is selected from the group consisting of an Atto dye, an Alexafluor dye, quantum dots, Hydroxycoumarin, Aminocouramin, Methoxycourmarin, Cascade Blue, Pacific Blue, Pacific Orange, Lucifer Yellow, NBD, R-Phycoerythrin (PE), PE-Cy5 conjugates, PE-Cy7 conjugates, Red 613, PerCP, TruRed, FluorX, Fluorescein, BODIPY-FL, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, TRITC, X-Rhodamine, Lissamine Rhocamine B, Texas Red, Allophycocyanin (APC), APC-Cy7 conjugates, Indo-1, Fluo-3, Fluo-4, DCFH, DHR, SNARF, GFP (Y66H mutation), GFP (Y66F mutation), EBFP, EBFP2, Azurite, GFPuv, T-Sapphire, Cerulean
  • the immune cell is a T cell. In some embodiments, the
  • T cell is disposed in vitro. In some embodiments, the T cell is disposed in vivo. In some embodiments, the T cell is in one of blood, extracted tissue, tissue grown ex vivo, and cell culture media.
  • the T cell is an autologous T cell.
  • the T cell is an allogenic T cell.
  • the dose comprises l.OxlO 6 cells per kg.
  • the antigen binding molecule comprises an antigen binding molecule of described herein and humanized forms thereof.
  • the present disclosure provides a method of isolating a cell comprising a CLL-1 binding molecule, the method comprising: (a) providing a sample known or suspected to comprise a molecule comprising a CLL-1 binding molecule; (b) providing an antigen binding molecule that specifically binds a molecule comprising a CLL- 1 binding molecule, optionally comprising a detectable label; (c) contacting the sample with the antigen binding molecule, under conditions that permit the formation of a binding complex comprising the molecule comprising a CLL-1 binding molecule and the antigen binding molecule; (d) separating any molecules not part of a binding complex from formed binding complexes; and (e) separating a formed binding complex into: (a) a molecule comprising a CLL-1 binding molecule, and (b) an antigen binding molecule.
  • the molecule comprising a CLL-1 binding molecule is a CAR.
  • the CAR further comprises a molecule, or a fragment thereof, selected from the group consisting of CD28, OX-40, 4-1BB/CD137, CD2, CD7, CD27, CD30, CD40, Programmed Death-1 (PD-1), inducible T cell co-stimulator (ICOS), lymphocyte function-associated antigen- 1 (LFA-1, CDl-la/CD18), CD3 gamma, CD3 delta, CD3 epsilon, CD3 zeta, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class 1 molecule, TNF receptor proteins, an Immunoglobulin protein, cytokine receptor, integrins, Signaling Lymphocytic Activation Molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, ICAM-1
  • the antigen binding molecule is disposed on a surface selected from the group consisting of an agarose bead, a magnetic bead, a plastic welled plate, a glass welled plate, a ceramic welled plate and a cell culture bag.
  • the detectable label is selected from the group consisting of a fluorescent label, a photochromic compound, a proteinaceous fluorescent label, a magnetic label, a radiolabel, and a hapten.
  • the fluorescent label is selected from the group consisting of an Atto dye, an Alexafluor dye, quantum dots, Hydroxycoumarin, Aminocouramin, Methoxycourmarin, Cascade Blue, Pacific Blue, Pacific Orange, Lucifer Yellow, NBD, R-Phycoerythrin (PE), PE-Cy5 conjugates, PE-Cy7 conjugates, Red 613, PerCP, TruRed, FluorX, Fluorescein, BODIPY-FL, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, TRITC, X-Rhodamine, Lissamine Rhocamine B, Texas Red, Allophycocyanin (APC), APC-Cy7 conjugates, Indo-1, Fluo-3, Fluo-4, DCFH, DHR, SNARF, GFP (Y66H mutation), GFP (Y66F mutation), EBFP, EBFP2, Azurite, GFPuv, T-Sapphire, Cerulean
  • the antigen binding molecule comprises an antigen binding molecule of described herein and humanized forms thereof.
  • the present disclosure provides a method of determining the presence or absence of a molecule comprising a CLL-1 binding molecule in a sample, the method comprising: (a) providing a sample known or suspected to comprise a molecule comprising a CLL-1 binding molecule; (b) providing an antigen binding molecule comprising a detectable label that specifically binds a molecule comprising a CLL-1 binding molecule; (c) contacting the sample with the antigen binding molecule under conditions that permit the formation of a binding complex; (d) separating any molecules not part of a binding complex from formed binding complexes; and (e) detecting the presence or absence of a binding complex.
  • the molecule comprising a CLL-1 binding molecule is a CAR.
  • the CAR further comprises a molecule, or a fragment thereof, selected from the group consisting of CD28, OX-40, 4-1BB/CD137, CD2, CD7, CD27, CD30, CD40, Programmed Death-1 (PD-1), inducible T cell co-stimulator (ICOS), lymphocyte function-associated antigen- 1 (LFA-1, CDl-la/CD18), CD3 gamma, CD3 delta, CD3 epsilon, CD3 zeta, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class 1 molecule, TNF receptor proteins, an Immunoglobulin protein, cytokine receptor, integrins, Signaling Lymphocytic Activation Molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, ICAM-1
  • the antigen binding molecule is disposed on a surface selected from the group consisting of an agarose bead, a magnetic bead, a plastic welled plate, a glass welled plate, a ceramic welled plate and a cell culture bag.
  • the detectable label is selected from the group consisting of a fluorescent label, a photochromic compound, a proteinaceous fluorescent label, a magnetic label, a radiolabel, and a hapten.
  • the fluorescent label is selected from the group consisting of an Atto dye, an Alexafluor dye, quantum dots, Hydroxycoumarin, Aminocouramin, Methoxycourmarin, Cascade Blue, Pacific Blue, Pacific Orange, Lucifer Yellow, NBD, R-Phycoerythrin (PE), PE-Cy5 conjugates, PE-Cy7 conjugates, Red 613, PerCP, TruRed, FluorX, Fluorescein, BODIPY-FL, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, TRITC, X-Rhodamine, Lissamine Rhocamine B, Texas Red, Allophycocyanin (APC), APC-Cy7 conjugates, Indo-1, Fluo-3, Fluo-4, DCFH, DHR, SNARF, GFP (Y66H mutation), GFP (Y66F mutation), EBFP, EBFP2, Azurite, GFPuv, T-Sapphire, Cerulean
  • the antigen binding molecule comprises an antigen binding molecule of described herein and humanized forms thereof.
  • the present disclosure provides a method of increasing the concentration of cells presenting a molecule comprising a CLL-1 binding molecule, the method comprising: (a) providing a sample comprising a cell known or suspected to present a molecule comprising a CLL-1 binding molecule; (b) providing an antigen binding molecule that specifically binds a molecule comprising a CLL-1 binding molecule, optionally comprising a detectable label; (c) contacting the sample with the antigen binding molecule under conditions that permit the formation of a binding complex comprising the molecule comprising a CLL-1 binding molecule and the antigen binding molecule; (d) removing any components not part of a binding complex; and (e) repeating steps (a)-(d) a desired number of times.
  • the molecule comprising a CLL-1 binding molecule is a CAR.
  • the cell is an immune cell selected from the group consisting of CD8+ T cells, CD4+ T cells, tumor infiltrating lymphocytes (TILs), NK cells, TCR- expressing cells, dendritic cells, and NK-T cells.
  • the CAR further comprises a molecule, or a fragment thereof, selected from the group consisting of CD28, OX-40, 4-1BB/CD137, CD2, CD7, CD27, CD30, CD40, Programmed Death-1 (PD-1), inducible T cell co-stimulator (ICOS), lymphocyte function-associated antigen- 1 (LFA-1, CDl-la/CD18), CD3 gamma, CD3 delta, CD3 epsilon, CD3 zeta, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class 1 molecule, TNF receptor proteins, an Immunoglobulin protein, cytokine receptor, integrins, Signaling Lymphocytic Activation Molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, ICAM-1
  • the detectable label is selected from the group consisting of a fluorescent label, a photochromic compound, a proteinaceous fluorescent label, a magnetic label, a radiolabel, and a hapten.
  • the fluorescent label is selected from the group consisting of an Atto dye, an Alexafluor dye, quantum dots, Hydroxycoumarin, Aminocouramin, Methoxycourmarin, Cascade Blue, Pacific Blue, Pacific Orange, Lucifer Yellow, NBD, R-Phycoerythrin (PE), PE-Cy5 conjugates, PE-Cy7 conjugates, Red 613, PerCP, TruRed, FluorX, Fluorescein, BODIPY-FL, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, TRITC, X-Rhodamine, Lissamine Rhocamine B, Texas Red, Allophycocyanin (APC), APC-Cy7 conjugates, Indo-1, Fluo-3, Fluo-4, DCFH, DHR, SNARF, GFP (Y66H mutation), GFP (Y66F mutation), EBFP, EBFP2, Azurite, GFPuv, T-Sapphire, Cerulean
  • the immune cell is a T cell. In some embodiments, the
  • T cell is disposed in vitro. In some embodiments, the T cell is disposed in vivo. In some embodiments, the T cell is in one of blood, extracted tissue, tissue grown ex vivo , and cell culture media.
  • the T cell is an autologous T cell. [0088] In some embodiments, the T cell is an allogenic T cell.
  • the dose comprises l.OxlO 6 cells per kg.
  • the antigen binding molecule comprises an antigen binding molecule of described herein and humanized forms thereof.
  • the present disclosure provides a method of depleting a population of immune cells presenting a molecule comprising a CLL-1 binding molecule, the method comprising: (a) providing a population of immune cells to be depleted, wherein the immune cells are known or suspected to be presenting a molecule comprising a CLL-1 binding molecule; and (b) contacting the immune cells with an antigen binding molecule that specifically binds to the molecule comprising a CLL-1 binding molecule, and an activating molecule expressed on the surface of the an immune cell not presenting the molecule comprising a CLL-1 binding molecule, under conditions that permit the formation of a ternary binding complex comprising the molecule comprising a CLL-1 binding molecule, the activating molecule and the antigen binding molecule.
  • the molecule comprising a CLL-1 binding molecule is a CAR.
  • the immune cell selected from the group consisting of CD8+ T cells, CD4+ T cells, tumor infiltrating lymphocytes (TILs), NK cells, TCR-expressing cells, dendritic cells, and NK-T cells.
  • the CAR further comprises a molecule, or a fragment thereof, selected from the group consisting of CD28, OX-40, 4-1BB/CD137, CD2, CD7, CD27, CD30, CD40, Programmed Death-1 (PD-1), inducible T cell co-stimulator (ICOS), lymphocyte function-associated antigen- 1 (LFA-1, CDl-la/CD18), CD3 gamma, CD3 delta, CD3 epsilon, CD3 zeta, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class 1 molecule, TNF receptor proteins, an Immunoglobulin protein, cytokine receptor, integrins, Signaling Lymphocytic Activation Molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, ICAM-1
  • the immune cell is a T cell. In some embodiments, the
  • T cell is disposed in vitro. In some embodiments, the T cell is disposed in vivo. In some embodiments, the T cell is in one of blood, extracted tissue, tissue grown ex vivo, and cell culture media.
  • the T cell is an autologous T cell.
  • the T cell is an allogenic T cell.
  • the dose comprises l.OxlO 6 cells per kg.
  • the antigen binding molecule comprises an antigen binding molecule of described herein and humanized forms thereof.
  • the antigen binding molecule comprises an antigen binding molecule disclosed herein, and humanized forms thereof.
  • Figure 1 depicts a series of histograms using CAR-expressing T cells demonstrating that KIP- 10 clonal supernatants (Clones 15-2, 63-2, 103-2, 147-1, 148-4, 160- 1 and 180-2) bind anti-CLL-1 CAR-expressing T cells (top row), but not two control CAR- expressing T cells; the plots demonstrate specific, selective binding of the antibodies to the expressed anti-CLL-1 CAR.
  • the present invention relates to anti -idiotypic antigen binding molecules, including antibodies, which specifically bind to antigen binding molecules that specifically bind CLL-1.
  • Polynucleotides encoding the antigen binding molecules, as well as vectors comprising the polynucleotides, and in vitro cells comprising the polynucleotides and vectors, are also disclosed.
  • the antigen binding molecules, polynucleotides, vectors, in vitro cells and methods described herein may be used in a range of applications, e.g ., as reagents to detect the presence of moieties comprising the CLL-1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules, quantifying the amount of a moiety comprising CLL-1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules, screening for moieties comprising the CLL-1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules, purifying moieties comprising a CLL-1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules, and biomarker studies focused on moieties comprising a CLL-1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules.
  • Therapeutic uses are also provided, for example applications in which the biological activity of a moiety comprising a CLL-1 binding molecule, as well as cells presenting such molecules, is modulated (enhanced or repressed), as well as dose ranging studies related to therapeutics comprising a CLL-1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules, and cells presenting such molecules.
  • antigen binding molecules disclosed herein were generated from hybridomas generated using B-cells of rabbit origin, but may be readily humanized using standard methods known to those of skill in the art, as well as those described herein. Representative humanized forms of the disclosed antigen binding molecules may be generated as described herein.
  • the twenty conventional (e.g . , naturally occurring) amino acids and their abbreviations follow conventional usage. See, e.g., Immunology - A Synthesis (2nd Edition), Golub and Green, eds., Sinauer Assoc., Sunderland, Mass. (1991), which is incorporated herein by reference for any purpose.
  • Stereoisomers e.g., D-amino acids
  • unnatural amino acids such as alpha-, alpha-di substituted amino acids, N-alkyl amino acids, lactic acid, and other unconventional amino acids may also be suitable components for polypeptides of the present invention.
  • Examples of unconventional amino acids include: 4-hydroxyproline, gamma-carboxyglutamate, epsilon- N,N,N-trimethyllysine, e-N-acetyllysine, O-phosphoserine, N-acetylserine, N- formylmethionine, 3-methylhistidine, 5-hydroxylysine, sigma-N-methylarginine, and other similar amino acids and imino acids (e.g, 4-hydroxyproline).
  • the left-hand direction is the amino terminal direction and the right-hand direction is the carboxy -terminal direction, in accordance with standard usage and convention.
  • the term “about” refers to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined, i.e., the limitations of the measurement system.
  • “about” or “comprising essentially of’ may mean within one or more than one standard deviation per the practice in the art.
  • “about” or “comprising essentially of’ may mean a range of up to 10% (i.e., ⁇ 10%).
  • about 5mg may include any number between 4.5 mg and 5.5 mg.
  • the terms may mean up to an order of magnitude or up to 5-fold of a value.
  • the meaning of “about” or “comprising essentially of’ should be assumed to be within an acceptable error range for that particular value or composition.
  • any concentration range, percentage range, ratio range or integer range is to be understood to be inclusive of the value of any integer within the recited range and, when appropriate, fractions thereof (such as one-tenth and one-hundredth of an integer), unless otherwise indicated.
  • the term “and/or” is to be understood as specific disclosure of each of the two specified features or components with or without the other.
  • the term “and/or” as used in a phrase such as “A and/or B” herein is intended to include “A and B,” “A or B,” “A” (alone), and “B” (alone).
  • the term “and/or,” as used in a phrase such as ‘A, B, and/or C” is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
  • allogeneic refers to any material derived from one individual which is then introduced to another individual of the same species, e.g., allogeneic T cell transplantation.
  • an antibody includes, without limitation, a glycoprotein immunoglobulin which binds specifically to an antigen.
  • an antibody may comprise at least two heavy (HC) chains and two light (LC) chains interconnected by disulfide bonds, or an antigen binding molecule thereof.
  • Each HC chain comprises a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region.
  • the heavy chain constant region comprises three constant domains, CHI, CH2 and CH3.
  • Each LC chain comprises a light chain variable region (abbreviated herein as VL) and a light chain constant region.
  • the light chain constant region comprises one constant domain, CL.
  • the VH and VL regions may be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR).
  • CDRs complementarity determining regions
  • FR framework regions
  • Each VH and VL comprises three CDRs and four FRs, arranged from amino-terminus to carboxy -terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • the variable regions of the heavy and light chains contain a binding domain that interacts with an antigen.
  • the constant regions of the Abs may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g ., effector cells) and the first component of the classical complement system (Clq).
  • antibody also encompasses an intact immunoglobulin or an antigen binding portion thereof that competes with the intact antibody for specific binding, unless otherwise specified.
  • Antigen binding portions may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies.
  • Antigen binding portions include, inter alia, Fab, Fab’, F(ab’)2, Fv, domain antibodies (dAbs), fragments including complementarity determining regions (CDRs), single-chain antibodies (scFv), chimeric antibodies, diabodies, triabodies, tetrabodies, and polypeptides that contain at least a portion of an immunoglobulin that is sufficient to confer specific antigen binding to the polypeptide.
  • antibody includes, both naturally occurring and non-naturally occurring (recombinantly-produced) antibodies, human and non-human antibodies, monospecific antibodies, multispecific antibodies (including bispecific antibodies), immunoglobulins, synthetic antibodies, tetrameric antibodies comprising two heavy chain and two light chain molecules, an antibody light chain monomer, an antibody heavy chain monomer, an antibody light chain dimer, an antibody heavy chain dimer, an antibody light chain-antibody heavy chain pair, intrabodies (see, e.g., Stocks, (2004) Drug Discovery Today 9(22):960-66), antibody fusions (which term encompasses antibody-drug conjugates) and which are sometimes referred to herein as “antibody conjugates”), heteroconjugate antibodies, single domain antibodies, monovalent antibodies, single chain antibodies or single-chain Fvs (scFv), camelized antibodies, affybodies, Fab fragments, F(ab’)2 fragments, disulfide-linked Fvs (sdFv), anti -idiotyp
  • a non-human antibody may be humanized using recombinant methods to reduce its immunogenicity in humans, as disclosed herein, with respect to antibodies that specifically bind a CLL-1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules.
  • the term “antibody” also includes an antigen-binding fragment of an antigen binding molecule of any of the aforementioned immunoglobulins, and includes a monovalent and a divalent fragment or portion, and a single chain antibody (e.g, a scFv).
  • an antibody specifically binds a CLL-1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules.
  • the antibody specifically binds to a CAR (or component thereof) comprising a CLL-1 binding molecule, as well as molecules comprising this sequence, and cells presenting such molecules; cells presenting a CLL-1 binding molecule may, but need not be, an immune cell, such as a T cell.
  • the term “antigen” means any molecule that provokes an immune response or is capable of being bound by an antibody or other antigen binding molecule.
  • the immune response may involve either antibody production, or the activation of specific immunologically-competent cells, or both.
  • any macromolecule including virtually all proteins or peptides (including a CLL-1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules), may serve as an antigen.
  • an antigen may be endogenously expressed, i.e. expressed by genomic DNA, or it may be recombinantly expressed, or it may be chemically synthesized.
  • an antigen comprises all or a portion of a CLL-1 binding molecule a CLL-1 binding molecule, as well as molecules comprising this sequence, which is optionally conjugated to an adjuvant such as keyhole limpet hemocyanin (KLH), or to an Fc to facilitate screening.
  • KLH keyhole limpet hemocyanin
  • the term “antigen binding molecule” means a protein comprising a portion that binds to an antigen or target protein and, optionally, a scaffold or framework portion that allows the antigen binding portion to adopt a conformation that promotes binding of the antigen binding molecule to the antigen.
  • antigen binding molecules examples include a scFv, a human, mouse or rabbit antibody; a humanized antibody; a chimeric antibody; a recombinant antibody; a single chain antibody; a diabody; a triabody; a tetrabody; a Fab fragment; a F(ab’)2 fragment; an IgD antibody; an IgE antibody; an IgM antibody; an IgGl antibody; an IgG2 anti-body; an IgG3 antibody; or an IgG4 antibody, and fragments thereof.
  • An antigen binding molecule may comprise, for example, an alternative protein scaffold or artificial scaffold with grafted complementarity determining regions (CDRs) or CDR derivatives.
  • CDRs complementarity determining regions
  • Such scaffolds include, but are not limited to, antibody-derived scaffolds comprising mutations introduced to, for example, stabilize the three-dimensional structure of the antigen binding molecule as well as wholly synthetic scaffolds comprising, for example, a biocompatible polymer. See , e.g., Korndorfer et al., 2003, Proteins: Structure, Function, and Bioinformatics, 53(1): 121-129 (2003); Roque et al., Biotechnol. Prog. 20:639- 654 (2004).
  • peptide antibody mimetics may be used, as well as scaffolds based on antibody mimetics utilizing various components (e.g, fibronectin) as a scaffold.
  • An antigen binding molecule may have, for example, the structure of a naturally occurring immunoglobulin.
  • An antigen binding molecule may have one or more binding sites. If there is more than one binding site, the binding sites may be identical to one another or they may be different. For example, a naturally occurring human immunoglobulin typically has two identical binding sites, while a “bispecific” or “bifunctional” antibody has two different binding sites, and is capable of specifically binding two different antigens (e.g, a CLL-1 binding molecule and a cell surface activator molecule).
  • a naturally occurring human immunoglobulin typically has two identical binding sites, while a “bispecific” or “bifunctional” antibody has two different binding sites, and is capable of specifically binding two different antigens (e.g, a CLL-1 binding molecule and a cell surface activator molecule).
  • an antigen binding molecule is an antibody or fragment thereof, including one or more of the complementarity determining regions (CDRs) disclosed herein (e.g., Table C and D), which specifically bind a CLL-1 binding molecule, as well as molecules comprising a CLL-1 binding molecule, and cells presenting such molecules.
  • CDRs complementarity determining regions
  • the antigen binding molecule binds to a CAR comprising a CLL-1 binding molecule, as well as molecules comprising a CLL-1 binding molecule, and may be expressed on an immune cell, such as a T cell.
  • autologous refers to any material derived from the same individual to which it is later to be re-introduced.
  • eACTTM engineered autologous cell therapy
  • binding affinity means the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g, an antigen binding molecule such as an antibody) and its binding partner (e.g, an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g, antibody and antigen).
  • the affinity of a molecule X for its partner Y may generally be represented by the dissociation constant (KD). Affinity may be measured and/or expressed in a number of ways known in the art, including, but not limited to, equilibrium dissociation constant (KD), and equilibrium association constant (KA).
  • the KD is calculated from the quotient of k 0ff /k 0n
  • KA is calculated from the quotient of k 0n /k 0ff
  • k 0n refers to the association rate constant of, e.g ., an antibody to an antigen
  • k 0ff refers to the dissociation of, e.g, an antibody to an antigen.
  • the k 0n and k 0ff may be determined by standard techniques known to one of ordinary skill in the art, such as BIAcore ® or KinExA or surface plasmon resonance.
  • CDR complementarity determining region
  • Framework regions may aid in maintaining the proper confirmation of the CDRs to promote binding between the antigen binding molecule and an antigen.
  • a number of definitions of the CDRs are commonly in use: Kabat numbering, Chothia numbering, AbM numbering, or contact numbering.
  • the AbM definition is a compromise between the Kabat and Chothia systems, and is used by Oxford Molecular's AbM antibody modelling software. Table A defines CDRs using each numbering system. The contact definition is based on an analysis of the available complex crystal structures.
  • Kabat numbering and like terms are recognized in the art and refer to a system of numbering amino acid residues in the heavy and light chain variable regions of an antibody, or an antigen binding molecule thereof.
  • the CDRs of an antibody may be determined according to the Kabat numbering system (see, e.g, Kabat et al. in Sequences of Proteins of Immunological Interest 5th Ed., NIH Publication 91-3242, Bethesda
  • CDRs within an antibody heavy chain molecule are typically present at amino acid positions 31 to 35, which optionally may include one or two additional amino acids, following 35 (referred to in the Kabat numbering scheme as 35A and 35B) (CDR1), amino acid positions 50 to 65 (CDR2), and amino acid positions 95 to 102 (CDR3).
  • CDRs within an antibody light chain molecule are typically present at amino acid positions 24 to 34 (CDR1), amino acid positions 50 to 56 (CDR2), and amino acid positions 89 to 97 (CDR3).
  • the CDRs of the antibodies described herein may be described according to the Kabat numbering scheme, as shown in Table C (although they may readily be construed in other numbering systems using Table A above).
  • the CDRs of an antibody may be determined according to the Chothia numbering scheme, which refers to the location of immunoglobulin structural loops (see, e.g., Chothia C & Lesk AM, (1987), J Mol Biol 196: 901-917; Al-Lazikani B et al, (1997) J Mol Biol 273: 927-948; Chothia C et al, (1992) J Mol Biol 227: 799-817; Tramontano A et al, (1990) J Mol Biol 215(1): 175-82; and U.S. Patent No. 7,709,226).
  • Chothia numbering scheme refers to the location of immunoglobulin structural loops
  • the Chothia CDR-H1 loop is present at heavy chain amino acids 26 to 32, 33, or 34
  • the Chothia CDR-H2 loop is present at heavy chain amino acids 52 to 56
  • the Chothia CDR-H3 loop is present at heavy chain amino acids 95 to 102
  • the Chothia CDR-L1 loop is present at light chain amino acids 24 to 34
  • the Chothia CDR-L2 loop is present at light chain amino acids 50 to 56
  • the Chothia CDR-L3 loop is present at light chain amino acids 89 to 97.
  • the end of the Chothia CDR-HI loop when numbered using the Kabat numbering convention varies between H32 and H34 depending on the length of the loop (this is because the Kabat numbering scheme places the insertions at H35A and H35B; if neither 35A nor 35B is present, the loop ends at 32; if only 35A is present, the loop ends at 33; if both 35A and 35B are present, the loop ends at 34). See Table A.
  • the CDRs of the antibodies described herein have been determined according to the Chothia numbering scheme, as shown in Table D.
  • a “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain.
  • Families of amino acid residues having side chains have been defined in the art. These families include amino acids with basic side chains (e.g, lysine, arginine, histidine), acidic side chains (e.g, aspartic acid, glutamic acid), uncharged polar side chains (e.g, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains ( e.g threonine, valine, isoleucine) and aromatic side chains (e.g, tyrosine, phenylalanine, tryptophan, histidine).
  • basic side chains e.
  • amino acid residues which are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. These include peptidomimetics and other reversed or inverted forms of amino acid moieties.
  • Naturally occurring residues may be divided into classes based on common side chain properties: hydrophobic: norleucine, Met, Ala, Val, Leu, lie; neutral hydrophilic: Cys, Ser, Thr, Asn, Gin; acidic: Asp, Glu; basic: His, Lys, Arg; residues that influence chain orientation: Gly, Pro; and aromatic: Trp, Tyr, Phe.
  • Non-conservative substitutions may involve the exchange of a member of one of these classes for a member from another class. Such substituted residues may be introduced, for example, into regions of a human antibody that are homologous with non human antibodies, or into the non-homologous regions of the molecule. Exemplary conservative amino acid substitutions are set forth in Table B below.
  • constant region and “constant domain” are interchangeable and have a meaning common in the art.
  • the constant region is an antibody portion, e.g ., a carboxyl terminal portion of a light and/or heavy chain which is not directly involved in binding of an antibody to antigen, but which may exhibit various effector functions, such as interaction with the Fc receptor.
  • the constant region of an immunoglobulin molecule generally has a more conserved amino acid sequence relative to an immunoglobulin variable domain.
  • cross competes means the situation in which the interaction between an antigen and a first antigen binding molecule or binding fragment thereof blocks, limits, inhibits, or otherwise reduces the ability of a reference antigen binding molecule or binding fragment thereof to interact with the antigen.
  • Cross competition may be complete, e.g, binding of the binding molecule to the antigen completely blocks the ability of the reference binding molecule to bind the antigen, or it may be partial, e.g. , binding of the binding molecule to the antigen reduces the ability of the reference binding molecule to bind the antigen.
  • an antigen binding molecule that cross competes with a reference antigen binding molecule binds the same or an overlapping epitope as the reference antigen binding molecule. In other embodiments, the antigen binding molecule that cross competes with a reference antigen binding molecule binds a different epitope than the reference antigen binding molecule.
  • Numerous types of competitive binding assays may be used to determine if one antigen binding molecule competes with another, for example: solid phase direct or indirect radioimmunoassay (RIA); solid phase direct or indirect enzyme immunoassay (EIA); sandwich competition assay (Stahli el al.
  • derivative refers to a molecule that includes a chemical modification other than an insertion, deletion, or substitution of amino acids (or nucleic acids).
  • derivatives comprise covalent modifications, including, but not limited to, chemical bonding with polymers, lipids, or other organic or inorganic moieties.
  • a chemically modified antigen binding molecule (a derivative) may have a greater circulating half-life than an antigen binding molecule that is not chemically modified.
  • a derivative antigen binding molecule is covalently modified to include one or more water soluble polymer attachments, including, but not limited to, polyethylene glycol, polyoxyethylene glycol, or polypropylene glycol.
  • the term “diabody” or dAB means bivalent antibodies comprising two polypeptide chains, wherein each polypeptide chain comprises VH and VL domains joined by a linker that is too short to allow for pairing between two domains on the same chain, thus allowing each domain to pair with a complementary domain on another polypeptide chain (see, e.g., Holliger et al, (1993) Proc Natl Acad Sci U.S.A. 90:6444-48, Poljak etal., (1994) Structure 2: 1121-23, and Perisic etal, (1994) Strucure 2(12): 1217-26).
  • polypeptide chains of a diabody are identical, then a diabody resulting from their pairing will have two identical antigen binding sites.
  • Polypeptide chains having different sequences may be used to make a diabody with two different antigen binding sites.
  • tribodies and tetrabodies are antibodies comprising three and four polypeptide chains, respectively, and forming three and four antigen binding sites, respectively, which may be the same or different.
  • an “epitope” is a term in the art and refers to a localized region of an antigen to which an antibody may specifically bind.
  • An epitope may be, for example, contiguous amino acids of a polypeptide (linear or contiguous epitope) or an epitope may, for example, come together from two or more non-contiguous regions of a polypeptide or polypeptides (conformational, non-linear, discontinuous, or non-contiguous epitope).
  • the epitope to which an antibody binds may be determined by, e.g ., NMR spectroscopy, X-ray diffraction crystallography studies, ELISA assays, hydrogen/deuterium exchange coupled with mass spectrometry (e.g, liquid chromatography electrospray mass spectrometry), array-based oligo-peptide scanning assays, and/or mutagenesis mapping (e.g, site-directed mutagenesis mapping).
  • crystallization may be accomplished using any of the known methods in the art (e.g, Giege et ah, (1994) Acta Cry stallogr D Biol Crystallogr 50(Pt 4): 339-350; McPherson, (1990 ) Eur J Biochem 189: 1-23; Chayen, (1997) Structure 5: 1269-1274; McPherson, (1976) J Biol Chem 251 : 6300-6303).
  • Antibody antigen crystals may be studied using well known X- ray diffraction techniques and may be refined using computer software such as X-PLOR (Yale University, 1992, distributed by Molecular Simulations, Inc.; see , e.g., Meth Enzymol (1985) Vols 114 & 115, eds Wyckoff et al.,), and BUSTER (Bricogne, (1993) Acta Crystallogr D Biol Crystallogr 49(Pt 1): 37-60; Bricogne, (1997) Meth Enzymol 276A: 361- 423, ed. Carter; Roversi et al., (2000) Acta Crystallogr D Biol Crystallogr 56(Pt 10): 1316- 1323).
  • Mutagenesis mapping studies may be accomplished using any method known to one of skill in the art. See, e.g., Champe et al, (1995) J Biol Chem 270: 1388-94 and Cunningham & Wells, (1989) Science 244: 1081-85 for a description of mutagenesis techniques, including alanine and arginine scanning mutagenesis techniques.
  • Fab fragment is a monovalent fragment having the
  • a “F(ab’)2 fragment” is a bivalent fragment having two Fab fragments linked by a disulfide bridge at the hinge region; a “Fv fragment” has the VH and VL domains of a single arm of an antibody; and a “dAb fragment” has a VH domain, a VL domain, or an antigen-binding fragment of a VH or VL domain.
  • the terms “immunospecifically binds,” “immunospecifically recognizes,” “specifically binds,” and “specifically recognizes” are analogous terms and are used interchangeably in the context of antigen binding molecules, and means that a given molecule preferentially binds to an antigen (e.g ., epitope or immune complex) as such binding is understood by one skilled in the art.
  • an antigen binding molecule that specifically binds to an antigen may bind to other peptides or polypeptides, but with a comparatively lower affinity as determined by, e.g., immunoassays, BIAcore ® , KinExA 3000 instrument (Sapidyne Instruments, Boise, ID), or other assays known in the art.
  • molecules that specifically bind to an antigen bind to the antigen with a KA that is at least 2 logs, 2.5 logs, 3 logs, 4 logs or greater than the KA when the molecules bind to another antigen.
  • molecules that specifically bind to an antigen e.g, a
  • the antigen binding molecule specifically binds an antigen (e.g, a CLL-1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules) with “high affinity” when the Kd is about 1 x 10 9 M to about 5 x 10 9 M.
  • the antigen binding molecule specifically binds an antigen (e.g, an anti-CLL- 1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules) with “very high affinity” when the K d is 1 x 10 10 M to about 5 x 10 10 M.
  • an antigen e.g, an anti-CLL- 1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules
  • molecules that specifically bind to an antigen are provided.
  • molecules that specifically bind to an antigen do not cross react with other proteins that do not comprise a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules.
  • an antibody or fragment thereof that binds to a CLL-1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules, with higher affinity than to another unrelated antigen.
  • an antigen binding molecule e.g, an antibody
  • a CLL-1 binding molecule as well as molecules comprising this sequence and cells presenting such molecules, with a 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or higher affinity than to another, unrelated antigen as measured by, e.g ., a radioimmunoassay, surface plasm on resonance, or kinetic exclusion assay.
  • the extent of binding of an antigen binding molecule, antibody or antigen binding fragment thereof that specifically binds a CLL-1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules, described herein compared to an unrelated protein which does not comprise a CLL-1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules is less than 10%, 15%, or 20% of the binding of the antibody to linker fragment protein as measured by, e.g. , a radioimmunoassay.
  • the term “heavy chain” when used in reference to an antibody may refer to any distinct type, e.g., alpha (a), delta (d), epsilon (e), gamma (g) and mu (m), based on the amino acid sequence of the constant domain, which give rise to IgA, IgD, IgE, IgG and IgM classes of antibodies, respectively, including subclasses of IgG, e.g, IgGi, IgG2, IgG3 and IgG4.
  • immunoglobulin means an immune molecule from any of the commonly known isotypes, including but not limited to IgA, secretory IgA, IgG and IgM.
  • IgG subclasses are also well known to those in the art and include but are not limited to human IgGl, IgG2, IgG3 and IgG4. Many of the molecules described herein are immunoglobulins.
  • isotype means the antibody class or subclass (e.g, IgM or IgGl) that is encoded by the heavy chain constant region genes.
  • An immunoglobulin is a tetrameric molecule, normally composed of two identical pairs of polypeptide chains, each pair having one “light” (about 25 kDa) and one “heavy” chain (about 50-70 kDa).
  • the amino-terminal portion of each chain includes a variable region of about 100 to 130 or more amino acids primarily responsible for antigen recognition.
  • the carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function.
  • Human light chains are classified as kappa and lambda light chains.
  • Heavy chains are classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, or IgE, respectively.
  • the variable and constant regions are joined by a “J” region of about 12 or more amino acids, with the heavy chain also including a “D” region of about 10 more amino acids. See generally, Berzofsky & Berkower, Ch. 7 in Fundamental Immunology (Paul, W., ed., Lippincott Williams & Wilkins (2012); which chapter and volume is incorporated by reference in its entirety for all purposes).
  • the variable regions of each light/heavy chain pair form the antibody binding site such that an intact immunoglobulin has two primary binding sites.
  • Naturally occurring immunoglobulin chains exhibit the same general structure of relatively conserved framework regions (FR) joined by three hypervariable regions, also called complementarity determining regions or “CDRs.” From N-terminus to C-terminus, both light and heavy chains comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The assignment of amino acids to each domain may be done in accordance with the definitions of Rabat (see, e.g. , Rabat el al. in Sequences of Proteins of Immunological Interest.
  • in vitro cell refers to any cell that is cultured ex vivo.
  • An in vitro cell may include a human cell such as a T cell or dendritic cell, or it may include CHO, sP2/0, rabbit and other non-human cells.
  • the term “light chain” when used in reference to an antibody may refer to any distinct type, e.g. , kappa (K) or lambda (l) based on the amino acid sequence of the constant domains. Light chain amino acid sequences are known in the art. In specific embodiments, the light chain is a human light chain.
  • neutralizing refers to an antigen binding molecule, scFv, antibody, or a fragment thereof, that binds to a ligand (e.g, a moiety comprising a CLL-1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules) and prevents or reduces the biological effect of that ligand.
  • a ligand e.g, a moiety comprising a CLL-1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules
  • the antigen binding molecule, scFv, antibody, or a fragment thereof directly blocking a binding site on the ligand or otherwise alters the ligand’s ability to bind through indirect means (such as structural or energetic alterations in the ligand).
  • the antigen binding molecule, scFv, antibody, or a fragment thereof prevents the protein to which it is bound from performing a biological function.
  • the term “patient” means any human who is being treated for an abnormal physiological condition, such as cancer or has been formally diagnosed with a disorder, those without formally recognized disorders, those receiving medical attention, those at risk of developing the disorders, etc.
  • the terms “subject” and “patient” are used interchangeably herein and include both human and non-human animal subjects.
  • peptide As used herein, the terms “peptide,” “polypeptide,” and “protein” are used interchangeably herein, and mean a compound comprising amino acid residues covalently linked by peptide bonds.
  • a protein or peptide must contain at least two amino acids, but no limitation is placed on the maximum number of amino acids that may comprise a protein’s or peptide’s sequence.
  • polypeptide encompasses any peptide or protein comprising two or more amino acids joined to each other by peptide bonds.
  • the term refers to both short chains, which also commonly are referred to as peptides, oligopeptides and oligomers, and to longer chains, which generally are referred to as proteins.
  • Polypeptides include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, among others.
  • polypeptide includes natural peptides, recombinant peptides, synthetic peptides, or a combination thereof.
  • polypeptides and/or proteins have deletions from, additions to, and/or substitutions of one or more amino acids of antigen binding molecule.
  • Useful polypeptide fragments may include immunologically functional fragments of antigen binding molecules, including, not limited to, one or more CDR regions, variable domains of a heavy and/or light chain, a portion of other portions of an antibody chain, and the like.
  • Moieties that may be substituted for one or more amino acids of an antigen binding molecule include, e.g ., D or L forms of amino acids, an amino acid different from the amino acid normally found in the same position of an antigen binding molecule (relative to SEQ ID NOs: 1-82), deletions, non-naturally occurring amino acids, and chemical analogs of amino acids.
  • Peptide analogs are commonly used in the pharmaceutical industry as non peptide drugs with properties analogous to those of the template peptide and form an aspect of the instant disclosure. These types of non-peptide compound are termed “peptide mimetics” or “peptidomimetics.” See , e.g. , Fauchere, (1986) Adv. Drug Res. (Testa, ed.) 15:29-69; Veber & Freidinger, (1985) TINS, p.392; and Evans et al., (1987) J. Med. Chem , 30:1229-39, which are incorporated herein by reference for any purpose.
  • the term “percent identity” means the percent of identical residues between the amino acids or nucleotides in the compared molecules. For these calculations, gaps in alignments (if any) must be addressed by a particular mathematical model or computer program (i.e., an “algorithm”).
  • Methods that may be used to calculate the identity of the aligned nucleic acids or polypeptides include those described in Computational Molecular Biology (Lesk, ed.), (1988) New York: Oxford University Press; Biocomputing Informatics and Genome Projects (Smith, ed.), 1993, New York: Academic Press; Computer Analysis of Sequence Data. Part L (Griffin and Griffin, eds.), 1994, New Jersey: Humana Press; von Heinje, (1987) Sequence Analysis in Molecular Biology New York: Academic Press; Sequence Analysis Primer. (Gribskov and Devereux, eds.), 1991, New York: M. Stockton Press; and Carillo et ah, (1988) ./. Applied Math. 48:1073.
  • the sequences being compared are aligned in a way that gives the largest match between the sequences.
  • the computer program used to determine percent identity may be, e.g ., MOE (Chemical Computing Group) or DNASTAR (University of Wisconsin, Madison, WI).
  • the computer algorithm GAP may be used to align the two polypeptides or polynucleotides for which the percent sequence identity is to be determined.
  • the sequences are aligned for optimal matching of their respective amino acid or nucleotide (the “matched span,” as determined by the algorithm).
  • a gap opening penalty (which is calculated as 3x the average diagonal, wherein the “average diagonal” is the average of the diagonal of the comparison matrix being used; the “diagonal” is the score or number assigned to each perfect amino acid match by the particular comparison matrix) and a gap extension penalty (which is usually 1/10 times the gap opening penalty), as well as a comparison matrix such as PAM 250 or BLOSUM 62 are used in conjunction with the algorithm.
  • a standard comparison matrix (see, e.g. , Dayhoff et al., (1978) Atlas of Protein Sequence and Structure 5:345-352 for the PAM 250 comparison matrix; Henikoff et al., (1992) Proc. Natl. Acad. Sci. U.S.A. 89: 10915-10919 for the BLOSUM 62 comparison matrix) is also used by the algorithm.
  • Certain alignment schemes for aligning two amino acid sequences may result in matching of only a short region of the two sequences, and this small aligned region may have very high sequence identity even though there is no significant relationship between the two full-length sequences. Accordingly, the selected alignment method (e.g, the GAP program) may be adjusted if desired to result in an alignment that spans at least 50 contiguous amino acids of the target polypeptide.
  • the selected alignment method e.g, the GAP program
  • single-chain antibody and “single chain fragment variable (scFv)” are used interchangeably and mean an antigen binding molecule in which a VL and a VH region are joined via a linker to form a continuous protein chain wherein the linker is long enough to allow the protein chain to fold back on itself and form a monovalent antigen binding site (see, e.g., Bird etal, (1988 ) Science 242:423-26 and Huston etal, (1988) Proc. Natl. Acad. Sci. U.S.A. 85:5879-83 (1988).
  • scFv single chain fragment variable
  • sample encompasses any sample obtained from a biological source.
  • biological sample may, by way of non-limiting example, include skin tissue, liver tissue, kidney tissue, lung tissue, cerebrospinal fluid (CSF), blood, amniotic fluid, sera, urine, feces, epidermal sample, skin sample, cheek swab, sperm, amniotic fluid, cultured cells, bone marrow sample and/or chorionic villi.
  • CSF cerebrospinal fluid
  • a biological sample may also be, e.g., a sample obtained from any organ or tissue (including a biopsy or autopsy specimen), may comprise cells (whether primary cells or cultured cells), medium conditioned by any cell, tissue or organ, tissue culture.
  • biological samples suitable for the invention are samples which have been processed to release or otherwise make available a peptide for detection as described herein. Fixed or frozen tissues also may be used.
  • “therapeutically effective dosage” of a therapeutic agent is any amount that, when used alone or in combination with another therapeutic agent, protects a subject against the onset of a disease or promotes disease regression evidenced by a decrease in severity of disease symptoms, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction.
  • the ability of a therapeutic agent to promote disease regression may be evaluated using a variety of methods known to the skilled practitioner, such as in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or by assaying the activity of the agent in in vitro assays.
  • the vector is a retroviral vector, a DNA vector, an RNA vector, an adenoviral vector, a baculoviral vector, an Epstein Barr viral vector, a papovaviral vector, a vaccinia viral vector, a herpes simplex viral vector, an adenovirus associated vector, a lentiviral vector, or any combination thereof.
  • variable region or “variable domain” are used interchangeably and mean a portion of an antibody, generally, a portion of a light or heavy chain, typically about the amino-terminal end of the antibody and comprising about 100-130 amino acids in the heavy chain and about 90 to 115 amino acids in the light chain, which differ extensively in sequence among antibodies and are used in the binding and specificity of a particular antibody for its particular antigen.
  • the variability in sequence is concentrated in those regions called complementarity determining regions (CDRs) while the more highly conserved regions in the variable domain are called framework regions (FR).
  • CDRs complementarity determining regions
  • FR framework regions
  • variable region of an antigen binding molecule is a human variable region.
  • the variable region comprises rodent, human or murine CDRs and human framework regions (FRs).
  • the variable region is a primate ( e.g ., a non-human primate) variable region.
  • the variable region is a rabbit variable region.
  • the variable region comprises human CDRs and non-human (e.g., rabbit, murine, rat or non human primate) framework regions (FRs).
  • the variable region comprises non-human (e.g., rabbit, murine, rat or non-human primate) CDRs and human framework regions (FRs).
  • VH VH domain
  • VH chain VH chain
  • VL VL domain
  • VL chain VL chain
  • the present disclosure is directed to antigen binding molecules, including antibodies, that specifically bind a CLL-1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules, and/or those which cross compete with one or more antigen binding molecules described herein.
  • Polynucleotides encoding the antigen binding molecules are also provided, and form an aspect of the instant disclosure.
  • An antibody or antigen binding molecule encoded of the present invention may be single chained or double chained.
  • the antibody or antigen binding molecule is single chained.
  • the antigen binding molecule is selected from the group consisting of an scFv, a Fab, a Fab’, a Fv, a F(ab’)2, a dAb, and any combination thereof.
  • the antibody or antigen binding molecule comprises an scFv.
  • an antigen binding molecule such as an antibody comprises a single chain, wherein the heavy chain variable region and the light chain variable region are connected by a linker (e.g ., an scFv).
  • a linker e.g ., an scFv.
  • the VH is located at the N terminus of the linker and the VL is located at the C terminus of the linker.
  • the VL is located at the N terminus of the linker and the VH is located at the C terminus of the linker.
  • the linker comprises at least about 5, at least about 8, at least about 10, at least about 13, at least about 15, at least about 18, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, or at least about 100 amino acids. In some embodiments, the linker comprises between about 8 amino acids and about 18 amino acids (e.g., 10 amino acids).
  • the antigen binding molecules of the present invention specifically bind to a CLL-1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules.
  • an antigen binding molecule of the present disclosure specifically binds a CLL-1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules with a KD of less than 1 x 10 6 M, less than 1 x 10 7 M, less than 1 x 10 8 M, or less than 1 x 10 9 M.
  • an antigen binding molecule specifically binds to a CLL-1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules, with a KD of less than 1 x 10 7 M.
  • an antigen binding molecule specifically binds a CLL-1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules, with a KD of less than 1 x 10 8 M.
  • an antigen binding molecule binds a CLL-1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules, with a KD of about 1 x 10 7 M, about 2 x 10 7 M, about 3 x 10 7 M, about 4 x 10 7 M, about 5 x 10 7 M, about 6 x 10 7 M, about 7 x 10 7 M, about 8 x 10 7 M, about 9 x 10 7 M, about 1 x 10 8 M, about 2 x 10 8 M, about 3 x 10 8 M, about 4 x 10 8 M, about 5 x 10 8 M, about 6 x 10 8 M, about 7 x 10 8 M, about 8 x 10 8 M, about
  • KD may be calculated using standard methodologies, as described herein.
  • an antigen binding molecule of the instant disclosure is an antibody identified herein as Clones 15-2, 63-2, 103-2, 147-1, 148-4, 160-1 and 180-2 and each comprises the heavy and light chain amino acid, coding, variable, and CDR sequences, as provided and labeled herein.
  • the antigen binding molecules of the present disclosure are antibodies and antigen binding fragments thereof.
  • the antibodies of the present disclosure comprise at least one CDR set forth in Tables C and D below.
  • the present disclosure provides hybridomas capable of producing the antibodies disclosed herein, and also methods of producing antibodies from hybridomas, as described herein and as known in the art.
  • Humanized antibodies are described herein and may be prepared by known techniques.
  • a humanized monoclonal antibody comprises the variable domain of a murine or rabbit antibody (or all or part of the antigen binding site thereof) and a constant domain derived from a human antibody.
  • a humanized antibody fragment may comprise an antigen binding site of a murine or rabbit monoclonal antibody and a variable domain fragment (lacking the antigen binding site) derived from a human antibody.
  • Procedures for the production of engineered monoclonal antibodies include those described inRiechmann etal. , (1988 ) Nature 332:323, Liu etal. , (1987) Proc. Nat. Acad. Sci.
  • the chimeric antibody is a CDR grafted antibody.
  • Techniques for humanizing antibodies are discussed in, e.g, U.S. Pat. Nos. 5,869,619; 5,225,539; 5,821,337; 5,859,205; 6,881,557; Padlan et al., (1995) FASEB J. 9:133-39; Tamura et al., (2000) J. Immunol. 164:1432-41; Zhang et al. , (2005) Mol. Immunol.
  • An antigen binding molecule of the present invention may also be a fully human monoclonal antibody.
  • Fully human monoclonal antibodies may be generated by any number of techniques with which those having ordinary skill in the art will be familiar. Such methods include, but are not limited to, Epstein Barr Virus (EBV) transformation of human peripheral blood cells (e.g., containing B lymphocytes), in vitro immunization of human B- cells, fusion of spleen cells from immunized transgenic mice carrying inserted human immunoglobulin genes, isolation from human immunoglobulin V region phage libraries, or other procedures as known in the art and based on the disclosure herein.
  • EBV Epstein Barr Virus
  • mice in which one or more endogenous immunoglobulin genes have been inactivated by various means have been prepared.
  • Human immunoglobulin genes have been introduced into the mice to replace the inactivated mouse genes.
  • elements of the human heavy and light chain locus are introduced into strains of mice derived from embryonic stem cell lines that contain targeted disruptions of the endogenous heavy chain and light chain loci (see also Bruggemann etal, (1997) Curr. Opin. Biotechnol. 8:455-58).
  • An additional method for obtaining antigen binding molecules of the invention is by the use of phage display, which is well-established for this purpose. See, e.g, Winter et al, (1994) Ann. Rev. Immunol. 12:433-55; Burton et al, (1994) Adv. Immunol 57:191-280.
  • Human or murine immunoglobulin variable region gene combinatorial libraries may be created in phage vectors that may be screened to select Ig fragments (Fab, Fv, sFv, or multimers thereof) that bind a CLL-1 binding molecule, as well as molecules comprising this sequence and cells presenting such molecules. See, e.g., U.S. Pat. No.
  • a library containing a plurality of polynucleotide sequences encoding Ig variable region fragments may be inserted into the genome of a filamentous bacteriophage, such as Ml 3 or lambda phage (kImmunoZapTM(H) and l ⁇ m m un oZapTM( L ) vectors (Stratagene, La Jolla, Calif) may also be used in this approach) or a variant thereof, in frame with the sequence encoding a phage coat protein.
  • a filamentous bacteriophage such as Ml 3 or lambda phage (kImmunoZapTM(H) and l ⁇ m m un oZapTM( L ) vectors (Stratagene, La Jolla, Calif) may also be used in this approach) or a variant thereof, in frame with the sequence encoding a phage coat protein.
  • mRNA is isolated from a B-cell population, and used to create heavy and light chain immunoglobulin cDNA expression libraries in the ZImmunoZapTM(H) and l Im m un oZapTM( L ) vectors. These vectors may be screened individually or co-expressed to form Fab fragments or antibodies. Positive plaques may subsequently be converted to a non- lytic plasmid that allows high level expression of monoclonal antibody fragments from E. coli.
  • variable regions of a gene expressing a monoclonal antibody of interest are amplified using nucleotide primers.
  • These primers may be synthesized by one of ordinary skill in the art, or may be purchased from commercial sources, which also sell primers for mouse and human variable regions including, among others, primers for VHa, VHb, VH c , VM, CHI, VL and CL regions).
  • These primers may be used to amplify heavy or light chain variable regions, which may then be inserted into vectors such as l ⁇ m m un oZ apTM( H ) and ZImmunoZapTM(L) (Stratagene), respectively.
  • vectors may then be introduced into E. coli , yeast, or mammalian-based systems for expression. Large amounts of a single-chain protein containing a fusion of the VH and VL domains may be produced using these methods.
  • the specific antibody genes may be cloned by isolating and amplifying DNA or mRNA therefrom according to standard procedures as described herein.
  • the antibodies produced therefrom may be sequenced and the CDRs identified and the DNA coding for the CDRs may be manipulated as described previously to generate other antibodies according to the invention.
  • An alternative method for production of a murine monoclonal antibody is to inject the hybridoma cells into the peritoneal cavity of a syngeneic mouse, for example, a mouse that has been treated (e.g ., pristane-primed) to promote formation of ascites fluid containing the monoclonal antibody.
  • Monoclonal antibodies may be isolated and purified by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion- exchange chromatography (see, e.g., Baines and Thorpe, (1992) in Methods in Molecular Biology 10:79-104 (The Humana Press).
  • Monoclonal antibodies may be purified by affinity chromatography using an appropriate ligand selected based on particular properties of the antibody (e.g, heavy or light chain isotype, binding specificity, etc.).
  • an appropriate ligand selected based on particular properties of the antibody (e.g, heavy or light chain isotype, binding specificity, etc.).
  • a suitable ligand, immobilized on a solid support include Protein A, Protein G, an anti-constant region (light chain or heavy chain) antibody, and an anti-idiotype antibody.
  • antigen binding molecules were produced in a rabbit system, human, partially human, or humanized antibodies may be suitable for many applications, particularly those involving administration of the antibody to a human subject, other types of antigen binding molecules will be suitable for certain applications.
  • Such antibodies may be prepared as described herein and form an aspect of the instant disclosure.
  • the antibody or antigen binding molecule that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting this sequence comprises any one, two, and/or three VH CDR sequences disclosed herein.
  • the antibody or antigen binding molecule comprises a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequence of any VH CDR1, VH CDR2, and VH CDR3 disclosed herein, respectively.
  • the antibody or antigen binding molecule comprises any one, two, and/or three VL CDR sequences disclosed herein.
  • the antibody or antigen binding molecule comprises a VL CDR1, a VL CDR2, and a VL CDR3 having the amino acid sequence of any VL CDR1, VL CDR2, and VL CDR3 disclosed herein, respectively.
  • the antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting this sequence comprises a VH CDR1, a VH CDR2, and VH CDR3, wherein the VH CDR1, VH CDR2, and VH CDR3 comprise the amino acid sequence of the VH CDR1, VH CDR2, and VH CDR3 sequences presented in Table C or D.
  • the instant disclosure provides antigen binding molecules that specifically bind to a CLL-1 binding molecule and subsequences thereof, molecules comprising this sequence and cells presenting such molecules. Antigen binding molecules that cross compete with the disclosed antigen binding molecules disclosed herein for an aspect of the disclosure.
  • the polynucleotides of the present invention encodes an antibody or antigen binding molecule that specifically binds a CLL-1 binding molecule, as well as molecules comprising these sequences and cells presenting such molecules, wherein the antibody or antigen binding molecule binds the same or an overlapping epitope as a reference antibody disclosed herein.
  • the antibody or antigen binding molecule binds the same or an overlapping epitope as a reference antibody.
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence VGYDMC (SEQ ID NO: 49).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence CIDTDSSSRTWNASWAK (SEQ ID NO: 50).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence NDDTSGWGSKL (SEQ ID NO: 51).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a heavy chain VH comprising: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence VGYDMC (SEQ ID NO: 49); and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence CIDTDSSSRTWNASWAK (SEQ ID NO: 50); and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence NDDTSGWGSKL (SEQ ID NO: 51).
  • the antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting this sequence comprises a heavy chain variable region sequence comprising an amino acid sequence of SEQ ID NO: 15.
  • the heavy chain variable region is 80%, 85%, 90%,
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence QASQTIGSALA (SEQ ID NO: 29).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence TASNLAS (SEQ ID NO: 30).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence QHTFYGTSYVDA (SEQ ID NO: 31).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a light chain VL comprising: (a) a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence QASQTIGSALA (SEQ ID NO: 29); and/or (b) a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence TASNLAS (SEQ ID NO: 30); and/or (c) a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence QHTFYGTSYVDA (SEQ ID NO: 31).
  • the antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting this sequence comprises a light chain variable region sequence comprising an amino acid sequence of SEQ ID NO: 22.
  • the light chain variable region is 80%, 85%, 90%,
  • an antigen binding molecule comprises (a) a VH comprising the amino acid sequence of SEQ ID NO: 15; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 22.
  • an antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 49; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 50; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 51; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 29; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 30; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 31.
  • the antibody or antigen binding molecule comprises:
  • 15-2 comprises:
  • CTGGTCACCGTCTCCTCA (SEQ ID NO: 1) re [0199] The nucleotide sequences encoding the light chain variable region of clone 15-
  • the antibody or antigen binding molecule comprises:
  • a heavy chain variable region comprising an amino acid sequence that is 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 15; and (b) a light chain variable region comprising an amino acid sequence that is 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 22.
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence SDYDMC (SEQ ID NO: 52).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence CIYAGSSDNTYYATWAK (SEQ ID NO: 53).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence DTADINFYFKL (SEQ ID NO: 54).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a heavy chain VH comprising: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence SDYDMC (SEQ ID NO: 52); and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence CIY AGS SDNT Y Y ATWAK (SEQ ID NO: 53); and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence DTADINFYFKL (SEQ ID NO: 54).
  • the antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting this sequence comprises a heavy chain variable region sequence comprising an amino acid sequence of SEQ ID NO: 16.
  • the heavy chain variable region is 80%, 85%, 90%,
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence QASESVSRWLA (SEQ ID NO: 32).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence SASTLAS (SEQ ID NO: 33).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence QGGYYSGGETYHNS (SEQ ID NO: 34).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a light chain VL comprising: (a) a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence QASESVSRWLA (SEQ ID NO: 32); and/or (b) a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence SASTLAS (SEQ ID NO: 33); and/or (c) a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence QGGYYSGGETYHN S (SEQ ID NO: 34).
  • the antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting this sequence comprises a light chain variable region sequence comprising an amino acid sequence of SEQ ID NO: 23.
  • the light chain variable region is 80%, 85%, 90%,
  • an antigen binding molecule comprises (a) a VH comprising the amino acid sequence of SEQ ID NO: 16; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 23.
  • an antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 52; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 53; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 54; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 32; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 33; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 34.
  • the antibody or antigen binding molecule comprises:
  • the antibody or antigen binding molecule comprises:
  • a heavy chain variable region comprising an amino acid sequence that is 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 16; and (b) a light chain variable region comprising an amino acid sequence that is 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 23.
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence SYYMS (SEQ ID NO: 55).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence IIYQSGNTDYASWAK (SEQ ID NO: 56).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence EGYAGYVGYSYNI (SEQ ID NO: 57).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a heavy chain VH comprising: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence SYYMS (SEQ ID NO: 55); and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence IIYQSGNTDYASWAK (SEQ ID NO: 56); and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence EGYAGYVGYSYNI (SEQ ID NO: 57).
  • the antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting this sequence comprises a heavy chain variable region sequence comprising an amino acid sequence of SEQ ID NO: 17.
  • the heavy chain variable region is 80%, 85%, 90%,
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence QASEDIESYLA (SEQ ID NO: 35).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence SASTLAS (SEQ ID NO: 33).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence QQGASSNDVEEP (SEQ ID NO: 36).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a light chain VL comprising: (a) a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence QASEDIESYLA (SEQ ID NO: 35); and/or (b) a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence SASTLAS (SEQ ID NO: 33); and/or (c) a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence QQGASSNDVEEP (SEQ ID NO: 36).
  • the antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting this sequence comprises a light chain variable region sequence comprising an amino acid sequence of SEQ ID NO: 24.
  • the light chain variable region is 80%, 85%, 90%,
  • an antigen binding molecule comprises (a) a VH comprising the amino acid sequence of SEQ ID NO: 17; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 24.
  • an antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 52; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 53; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 54; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 35; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 33; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 36.
  • the antibody or antigen binding molecule comprises:
  • 103-2 comprises:
  • the antibody or antigen binding molecule comprises:
  • a heavy chain variable region comprising an amino acid sequence that is 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 17; and (b) a light chain variable region comprising an amino acid sequence that is 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 24.
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence GDYYMC (SEQ ID NO: 58).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence CIYVGSYIYSFYASWAK (SEQ ID NO: 59).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence DPFATDSDVVSL (SEQ ID NO: 60).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a heavy chain VH comprising: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence GDYYMC (SEQ ID NO: 58); and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence CIYVGSYIYSFYASWAK (0SEQ ID NO: 59); and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence DPFATDSDVVSL (SEQ ID NO: 60).
  • the antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting this sequence comprises a heavy chain variable region sequence comprising an amino acid sequence of SEQ ID NO: 18.
  • the heavy chain variable region is 80%, 85%, 90%,
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence QASQSISTVLA (SEQ ID NO: 37).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence WASTLAS (SEQ ID NO: 38).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence AGYKSYSNDDGA (SEQ ID NO: 39).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a light chain VL comprising: (a) a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence QASQSISTVLA (SEQ ID NO: 37); and/or (b) a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence WASTLAS (SEQ ID NO: 38); and/or (c) a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence AGYKSYSNDDGA (SEQ ID NO: 39).
  • the antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting this sequence comprises a light chain variable region sequence comprising an amino acid sequence of SEQ ID NO: 25.
  • the light chain variable region is 80%, 85%, 90%,
  • an antigen binding molecule comprises (a) a VH comprising the amino acid sequence of SEQ ID NO: 18; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 25.
  • an antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 55; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 56; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 57; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 37; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 38; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 39.
  • the antibody or antigen binding molecule comprises:
  • 147-1 comprises:
  • the antibody or antigen binding molecule comprises:
  • a heavy chain variable region comprising an amino acid sequence that is 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 18; and (b) a light chain variable region comprising an amino acid sequence that is 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 25.
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence GSFDVC (SEQ ID NO: 61).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence CIVVDSSDRTWYASWAK (SEQ ID NO: 62).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence NDDTSGWGFNL (SEQ ID NO: 63).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a heavy chain VH comprising: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence GSFDVC (SEQ ID NO: 61); and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence CIVVDSSDRTWYASWAK (SEQ ID NO: 62); and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence NDDTSGWGFNL (SEQ ID NO: 63).
  • the antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting this sequence comprises a heavy chain variable region sequence comprising an amino acid sequence of SEQ ID NO: 19.
  • the heavy chain variable region is 80%, 85%, 90%,
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence QASQSIGSALA (SEQ ID NO: 40).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence TASNLAS (SEQ ID NO: 30).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence QCTYYGSSYINA (SEQ ID NO: 42).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a light chain VL comprising: (a) a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence QASQSIGSALA (SEQ ID NO: 40); and/or (b) a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence TASNLAS (SEQ ID NO: 30); and/or (c) a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence QCTYYGSSYINA (SEQ ID NO: 42).
  • the antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting this sequence comprises a light chain variable region sequence comprising an amino acid sequence of SEQ ID NO: 26.
  • the light chain variable region is 80%, 85%, 90%,
  • an antigen binding molecule comprises (a) a VH comprising the amino acid sequence of SEQ ID NO: 19; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 26.
  • an antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 61; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 62; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 63; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 40; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 30; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 42.
  • the antibody or antigen binding molecule comprises:
  • the antibody or antigen binding molecule comprises:
  • a heavy chain variable region comprising an amino acid sequence that is 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 19; and (b) a light chain variable region comprising an amino acid sequence that is 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 26.
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence SNYFVC (SEQ ID NO: 64).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence CINPGSGRTYSASWAK (SEQ ID NO: 65).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence DRPGSDDYYMRDL (SEQ ID NO: 66).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a heavy chain VH comprising: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence SNYFVC (SEQ ID NO: 64); and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence CINPGSGRTYSASWAK (SEQ ID NO: 65); and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence DRPGSDDYYMRDL (SEQ ID NO: 66).
  • the antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting this sequence comprises a heavy chain variable region sequence comprising an amino acid sequence of SEQ ID NO: 20.
  • the heavy chain variable region is 80%, 85%, 90%,
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence QASESIGSSLA (SEQ ID NO: 43).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence AASTLAS (SEQ ID NO: 44).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence QCSYYLNTYVGNP (SEQ ID NO: 45).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a light chain VL comprising: (a) a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence QASESIGSSLA (SEQ ID NO: 43); and/or (b) a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence AASTLAS (SEQ ID NO: 44); and/or (c) a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence QCSYYLNTYVGNP (SEQ ID NO: 45).
  • the antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting this sequence comprises a light chain variable region sequence comprising an amino acid sequence of SEQ ID NO: 27.
  • the light chain variable region is 80%, 85%, 90%,
  • an antigen binding molecule comprises (a) a VH comprising the amino acid sequence of SEQ ID NO: 20; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 27.
  • an antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 64; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 65; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 66; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 43; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 44; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 45.
  • the antibody or antigen binding molecule comprises:
  • 160-1 comprises:
  • the antibody or antigen binding molecule comprises:
  • a heavy chain variable region comprising an amino acid sequence that is 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 20; and (b) a light chain variable region comprising an amino acid sequence that is 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 27.
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence DNYYMC (SEQ ID NO: 67).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence CIYGGHIDTTYYASWVS (SEQ ID NO: 68).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence RTIYDDNDDYSYALHL (SEQ ID NO: 69).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a heavy chain VH comprising: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence DNYYMC (SEQ ID NO: 67); and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence CIY GGHIDTT YYAS W V S (SEQ ID NO: 68); and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence RTI YDDNDD Y S YALHL (SEQ ID NO: 69).
  • the antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting this sequence comprises a heavy chain variable region sequence comprising an amino acid sequence of SEQ ID NO: 21.
  • the heavy chain variable region is 80%, 85%, 90%,
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence QASQSISNLLA (SEQ ID NO: 46).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence GASNLES (SEQ ID NO: 47).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence QQGDSSSNLDNT (SEQ ID NO: 48).
  • an antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting such molecules comprises a light chain VL comprising: (a) a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence QASQSISNLLA (SEQ ID NO: 46); and/or (b) a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence GASNLES (SEQ ID NO: 47); and/or (c) a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence QQGDSSSNLDNT (SEQ ID NO: 48).
  • the antigen binding molecule or antibody that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting this sequence comprises a light chain variable region sequence comprising an amino acid sequence of SEQ ID NO: 28.
  • the light chain variable region is 80%, 85%, 90%,
  • an antigen binding molecule comprises (a) a VH comprising the amino acid sequence of SEQ ID NO: 21; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 28.
  • an antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 67; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 68; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 69; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 46; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 47; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 48.
  • the antibody or antigen binding molecule comprises:
  • 180-2 comprises:
  • the antibody or antigen binding molecule comprises:
  • a heavy chain variable region comprising an amino acid sequence that is 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 21; and (b) a light chain variable region comprising an amino acid sequence that is 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 28.
  • the present invention is also directed to polynucleotides encoding antibodies and other antigen binding molecules that specifically bind to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting this sequence.
  • a polynucleotide of the present invention encodes an antigen binding molecule, wherein the antigen binding molecule comprises a heavy chain variable region amino acid sequence that is at least about 75%, at least about 85%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to a heavy chain variable region amino acid sequence selected from the group consisting of SEQ ID NOs: 15-21.
  • a polynucleotide of the present invention encodes antigen binding molecule, wherein the antigen binding molecule comprises a light chain variable amino acid sequence that is at least about 75%, at least about 85%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to a light chain variable region amino acid sequence selected from the group consisting of SEQ ID NOs: 22-28.
  • the polynucleotide comprises a heavy chain variable region coding sequence selected from the group consisting of SEQ ID NO: 1-7. In embodiments, the polynucleotide comprises a light chain coding sequence selected from the group consisting of SEQ ID NO: 8-14.
  • vectors comprising a polynucleotide disclosed herein.
  • the present invention is directed to a vector or a set of vectors comprising a polynucleotide(s) encoding an amino acid sequence of an antibody or antigen binding molecule that specifically binds to a CLL-1 binding molecule and fragments thereof, molecules comprising this sequence and cells presenting this sequence, as described herein.
  • the vector is a viral vector.
  • the vector is a retroviral vector, a DNA vector, a murine leukemia virus vector, an SFG vector, a plasmid, a RNA vector, an adenoviral vector, a baculoviral vector, an Epstein Barr viral vector, a papovaviral vector, a vaccinia viral vector, a herpes simplex viral vector, an adenovirus associated vector (AAV), a lentiviral vector, or any combination thereof.
  • AAV adenovirus associated vector
  • cells comprising a polynucleotide or a vector of the present invention.
  • the present invention is directed to cells, in vitro cells, comprising a polynucleotide encoding an antigen binding molecule, as described herein.
  • the present invention is directed to cells, e.g ., in vitro cells, comprising a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting this sequence, as disclosed herein.
  • a host cell may be a prokaryotic cell, fungal cell, yeast cell, or higher eukaryotic cells such as a mammalian cell.
  • Suitable prokaryotic cells include, without limitation, eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobactehaceae such as Escherichia , e.g., E.
  • a host cell is a human cell.
  • a host cell is a CHO cell and in other embodiments a host cell is a sP2/0 or other murine cell.
  • a host cell of the present invention may be obtained through any source known in the art.
  • compositions comprising a polynucleotide described herein, a vector described herein, an antibody and/or an antigen binding molecule described herein, or an in vitro cell described herein.
  • the composition comprises a pharmaceutically acceptable carrier, diluent, solubilizer, emulsifier, preservative and/or adjuvant.
  • the composition comprises an excipient.
  • the composition comprises a polynucleotide encoding an antibody or antigen binding molecule that specifically binds to that specifically binds to a CLL-1 binding molecule and fragments thereof, molecules comprising this sequence and cells presenting this sequence.
  • the composition comprises an antigen binding molecule encoded by a polynucleotide of the present invention, wherein the antigen binding molecule specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting this sequence, as disclosed herein.
  • the composition comprises an in vitro cell comprising a polynucleotide encoding an antibody or an antigen binding molecule thereof encoded by a polynucleotide of the present invention.
  • the composition comprises one antibody or antigen binding molecule that specifically binds to a CLL-1 binding molecule and fragments thereof, molecules comprising this sequence and cells presenting this sequence, as disclosed herein.
  • the composition comprises more than one antibody or antigen binding molecule that specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting this sequence, as disclosed herein, wherein the antibodies or antigen binding molecules bind more than one epitope.
  • the antibodies or antigen binding molecules will not compete with one another for binding to that epitope.
  • two or more of the antibodies or antigen binding molecules provided herein are combined together in a pharmaceutical composition.
  • a composition will be suitable for administration to a subject, including a human.
  • the antigen binding molecule is selected from the group consisting of an antibody, an scFv, a Fab, a Fab’, a Fv, a F(ab’)2, a dAb, a human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a polyclonal antibody, a recombinant antibody, an IgE antibody, an IgD antibody, an IgM antibody, an IgGl antibody, an IgGl antibody having at least one mutation in the hinge region, an IgG2 antibody an IgG2 antibody having at least one mutation in the hinge region, an IgG3 antibody, an IgGl antibody having at least one mutation in the hinge region, an IgG4 antibody, an IgG4 antibody having at least one mutation in the hinge region, an antibody comprising at least one non-naturally occurring amino acid, and any combination thereof.
  • T cells may be employed. Such T cells may come from any source known in the art. For example, T cells may be differentiated in vitro from a hematopoietic stem cell population, or T cells may be obtained from a subject. T cells may be obtained from, e.g ., peripheral blood mononuclear cells (PBMCs), bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. In addition, the T cells may be derived from one or more T cell lines available in the art.
  • PBMCs peripheral blood mononuclear cells
  • the T cells may be derived from one or more T cell lines available in the art.
  • T cells may also be obtained from a unit of blood collected from a subject using any number of techniques known to the skilled artisan, such as FICOLLTM separation and/or apheresis. Additional methods of isolating T cells for a T cell therapy are disclosed in U.S. Patent Publication No. 2013/0287748, which is herein incorporated by references in its entirety.
  • an antigen binding molecule specifically binds to a CLL-1 binding molecule, molecules comprising this sequence and cells presenting this sequence, as disclosed herein.
  • the antigen binding molecule comprises one or more of (a) a light chain CDR1, (b) a light chain CDR2, (c) a light chain CDR3, (d) a heavy chain CDR1, (e) a heavy chain CDR2, and (f) a heavy chain CDR3.
  • an antigen binding molecule comprises a heavy chain CDR3 comprising one of SEQ ID NOs: 51, 54, 57, 60, 63, 66, and 69, or a light chain CDR3 comprising one of SEQ ID Nos: 31, 34, 36, 39, 42, 45, and 48, or both the heavy and light chain CDR3s.
  • the antigen binding molecule comprises a heavy chain CDR1 comprising an amino acid sequence comprising one of SEQ ID NOs: 49, 52, 55, 58, 61, 64, and 67, or a heavy chain CDR2 comprising the amino acid sequence of one of SEQ ID NOs: 50, 53, 56, 59, 62, 65, and 68, or a light chain CDR1 comprising the amino acid sequence of one of SEQ ID NOs: 29, 32, 35, 37, 40, 43, and 46 or a light chain CDR2 comprising the amino acid sequence of one of SEQ ID NOs: 30, 33, 38, 44, and 47.
  • a heavy chain CDR1 comprising an amino acid sequence comprising one of SEQ ID NOs: 49, 52, 55, 58, 61, 64, and 67
  • a heavy chain CDR2 comprising the amino acid sequence of one of SEQ ID NOs: 50, 53, 56, 59, 62, 65, and 68
  • a light chain CDR1 comprising the amino
  • the antigen binding molecule comprises a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2, and a light chain CDR3, each CDR comprising an amino acid sequence shown in Table C or D.
  • an antigen binding molecule comprises a heavy chain (HC), and the HC comprises a heavy chain variable region (VEl) sequence comprising one of SEQ ID NOs: 1-7 or 15-21.
  • the heavy chain comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3, each CDR comprising an amino acid sequence shown in Table C or D.
  • an antigen binding molecule may be employed which comprises a VH amino acid sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a VH of an antigen binding molecule of claim disclosed herein (e.g ., an antigen binding molecules comprising a variable region (VH) sequence comprising one of SEQ ID NOs: 15-21.
  • VH variable region
  • an antigen binding molecule comprises a light chain (LC), and the LC may comprise a heavy chain variable region (VL) sequence comprising one of SEQ ID NOs: 8-14 or 22-28.
  • the light chain comprises a light chain CDR1, a light chain CDR2, and a light chain CDR3, each CDR comprising an amino acid sequence shown in Table C or D.
  • an antigen binding molecule may be employed which comprises a VL amino acid sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a VL of an antigen binding molecule of claim disclosed herein (e.g., an antigen binding molecules comprising a variable region (VL) sequence comprising SEQ ID NO: 18-28).
  • VL variable region
  • a method of administering a dose of a medicament to a subject, the dose comprising a preselected number of cells presenting a therapeutic molecule comprising a CLL-1 binding molecule is provided.
  • the dose comprises 0.5 xlO 6 cells per kilogram of the subject, 1.OxlO 6 cells per kilogram of the subject, 2.0xl0 6 cells per kilogram of the subject, 3.0xl0 6 cells per kilogram of the subject, 4. OxlO 6 cells per kilogram of the subject, or 5. OxlO 6 cells per kilogram of the subject, although the method may be employed using any dose. l.OxlO 6 cells per kilogram of the subject is a preferred dose.
  • a subject is a human or non-human subject.
  • the subject may be, e.g ., any human who is being treated for an abnormal physiological condition, such as cancer or has been formally diagnosed with a disorder, those without formally recognized disorders, those receiving medical attention, those at risk of developing the disorders, those being studied for the presence or absence of a disorder, etc.
  • a sample of known volume comprising a population comprising a known number of cells, which cells are known or suspected to be presenting a molecule comprising a CLL-1 binding molecule.
  • the number of cells may be determined using any known method.
  • the cells are counted using an automated apparatus, such as a cell sorter (e.g ., a FACS), however traditional non-automated cell counting methods may also be employed.
  • a cell sorter e.g ., a FACS
  • the cells of the method may comprise any type of cell, with immune cells
  • T cells e.g., B lymphocytes, monocytes, dendritic cells, Langerhans cells, keratinocytes, endothelial cells, astrocytes, fibroblasts, and oligodendrocytes.
  • T cells including T cytotoxic, T helper and Treg cells
  • the cells are T cells, which may be obtained as described herein and by methods known in the art. Any type of cell may be employed in the method, and the cell may be a human or non-human cell (including both prokaryotic and eukaryotic cells).
  • Exemplary cells include, but are not limited to immune cells such as T cells, tumor infiltrating lymphocytes (TILs), NK cells, TCR-expressing cells, dendritic cells, and NK-T cells.
  • TILs tumor infiltrating lymphocytes
  • NK cells TCR-expressing cells
  • dendritic cells dendritic cells
  • NK-T cells NK cells
  • the T cells may be autologous, allogeneic, or heterologous.
  • the cells are T cells presenting a CAR.
  • the T cells may be CD4+ T cells or CD8+ T cells.
  • the T cell may be an in vivo T cell or an in vitro T cell.
  • the cells may be disposed in, or isolated from, any environment capable of maintaining the cells in a viable form, such as blood, tissue or any other sample obtained from a subject, cell culture media, tissue grown ex vivo, etc. Gradient purification, cell culture selection and/or cell sorting may also be employed in obtaining T cells.
  • the therapeutic molecule expressed by the cell may comprise any molecule known or suspected to provide a therapeutic benefit to a subject to which is it administered.
  • a therapeutic molecule may be a peptide or polypeptide of any structure or design.
  • the therapeutic molecule component is expressed or disposed, at least in part, extracellularly, i.e., to a degree that it may be recognized by an extracellular interaction partner such as the antigen binding molecules of the instant disclosure.
  • the therapeutic molecule is a CAR.
  • the therapeutic molecule may comprise a molecule, or fragment thereof, selected from the group consisting of CD28, OX-40, 4-1BB/CD137, CD2, CD7, CD27, CD30, CD40, Programmed Death-1 (PD-1), inducible T cell co-stimulator (ICOS), lymphocyte function- associated antigen-1 (LFA-1, CDl-la/CD18), CD3 gamma, CD3 delta, CD3 epsilon, CD3 zeta, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class 1 molecule, TNF receptor proteins, an Immunoglobulin protein, cytokine receptor, integrins, Signaling Lymphocytic Activation Molecules (SLAM proteins), activating NK cell receptors,
  • SLAM proteins Signaling Lymphocytic
  • an aliquot of the sample comprising a population of cells presenting a molecule comprising a CLL-1 binding molecule is provided.
  • the aliquot may be obtained using any convenient means, such as by a cell sorter, by a simply pipetting of material out of the sample, etc.
  • an antigen binding molecule that specifically binds a CLL-1 binding molecule further comprising a detectable label is provided.
  • the antigen binding molecule is preferably an antigen binding molecule disclosed herein, e.g ., sequence listing or the instant disclosure. Any detectable label may be employed in the method, as described herein, and suitable labels may be selected using a desired set of criteria.
  • detectable labels examples include fluorescent labels (e.g, an Atto dye, an Alexafluor dye, quantum dots, Hydroxycoumarin, Aminocoumarin, Methoxycoumarin, Cascade Blue, Pacific Blue, Pacific Orange, Lucifer yellow, NBD, R-Phycoerythrin (PE), PE-Cy5 conjugates, PE-Cy7 conjugates, Red 613, PerCP, TruRed, FluorX, Fluorescein, BODIPY-FL, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, TRITC, X-Rhodamine, Lissamine Rhodamine B, Texas Red, Allophycocyanin (APC), APC-Cy7 conjugates, Indo-1, Fluo-3, Fluo-4, DCFH, DHR, SNARF, GFP (Y66H mutation), GFP (Y66F mutation), EBFP, EBFP2, Azurite, GFPuv, T- Sapphire, Cerulean, mCFP, mT
  • Suitable optical dyes including fluoro-phores, are described in Johnson, Molecular Probes Handbook:A Guide to Fluorescent Probes and Labeling Techniques, 11 th Edition, Life Technologies, (2010), hereby expressly incorporated by reference, radiolabels (e.g ., isotope markers such as 3 H, U C, 14 C, 15 N, 18 F, 35 S, 64 CU, 90 Y, "Tc, U1 ln, 124 I, 125 I, 131 I), photochromic compounds, a Halo-tag, Atto dyes, Tracy dyes, proteinaceous fluorescent labels (e.g., proteinaceous fluorescent labels also include, but are not limited to, green fluorescent protein, including a Renilla, Ptilosarcus, or Aequorea species of GFP (Chalfie et al, (1994) Science 263:802-805), EGFP (Clon-tech Labs., Inc., Genbank Accession Number U55762), blue fluorescent protein (BFP, Quantum
  • the label may be associated with the antigen binding molecule at any position in the molecule, although it is preferable to associate the label with the molecule at a position (or positions, if multiple labels are employed) at a point such that the binding properties of the molecule are not modified (unless such modified binding activity is desired).
  • Any antigen binding molecule that specifically binds a CLL-1 binding molecule (or fragment thereof) may be employed.
  • suitable antigen binding molecules are provided herein, e.g, those having one or more of the CDRs shown in Table C or D.
  • the antigen binding molecule may be disposed on any surface, or no surface at all.
  • the antigen binding molecule may be present in a buffer and the buffer- antigen binding molecule may be contacted with the sample.
  • the antigen binding molecule may be associated with a surface. Suitable surfaces include agarose beads, magnetic beads such as DYNABEADS, or a plastic, glass or ceramic plate such as a welled plate, a bag such as a cell culture bag, etc.
  • the surface may itself be disposed in another structure, such as a column.
  • the aliquot of the sample is contacted with the antigen binding molecule under conditions that permit the formation of a binding complex comprising a cell present in the sample and the antigen binding molecule.
  • the result of this step of the method is the formation of a binding complex in which the antigen binding molecule, with which a detectable label is associated, is bound to the cell expressing the therapeutic molecule, which comprises a CLL-1 binding molecule.
  • the binding complex itself is detectable.
  • Conditions that permit the formation of a binding complex will be dependent on a variety of factors, however generally aqueous buffers at physiological pH and ionic strength, such as in phosphate-buffered saline (PBS), will favor formation of binding complexes and are preferred in the disclosed method.
  • PBS phosphate-buffered saline
  • the fraction of cells present in a binding complex of in the aliquot is then determined. This calculation may be performed by comparing the number of cells bearing the detectable label to those that do not, and may be represented as percentage. The number of cells in binding complexes may be determined. The specific method employed to determine the number of cells present in a binding complex will be dependent on the nature of the label selected. For example, FACS may be employed when a fluorescent label is selected; when an isotope label is selected mass spectrometry, NMR or other technique may be employed; magnetic-based cell sorting may be employed when a magnetic label is chosen; microscopy may also be employed. The number of cells in the sample is known ab initio and thus the fraction of cells present in a binding complex may be easily determined.
  • the concentration of cells in the initial sample expressing a molecule comprising a CLL-1 binding molecule is determined; the determination is based on the fraction of cells determined to be present in the binding complex, and thus expressing the therapeutic protein bearing a detectable label.
  • the fraction of cells presenting the therapeutic protein is known, and the volume of the aliquot is known; thus a simple comparison of the number of cells in the sample from which the aliquot was taken that are expressing the therapeutic molecule to the volume of the larger sample provides the fraction of the cells in the sample bearing the therapeutic molecule on a therapeutic molecule/volume basis (i.e., the concentration of cells bearing the therapeutic molecule in the larger sample).
  • the volume of the sample that comprises the selected number of cells is then determined, by extrapolation based on the concentration of cells bearing therapeutic molecule present in the sample.
  • the volume of sample comprising the desired number of cells is administered to the subject.
  • the administration may comprise an aspect of a therapeutic regimen based on the therapeutic molecule present in the sample and expressed by the cells in the sample.
  • an advantage of the method is that by administering a dose comprising the preselected number of cells, which number of cells will be determined based on a known or expected efficacy, unnecessary administration of cells presenting the therapeutic molecule is avoided; i.e., the subject receives the correct number of cells to provide a desired therapeutic benefit and is not overdosed with cells.
  • Vb Method of Determining a Number of Cells Presenting a Molecule of Interest
  • a sample comprising cells known or suspected to be expressing a molecule comprising the amino acid sequence of a CLL-1 binding molecule is provided.
  • the cell may be of any type, and may be human or non-human (e.g ., mouse, rate, rabbit, hamster, etc).
  • the cell is an immune cell.
  • An immune cell of the method may be any type of immune cell (e.g., B lymphocytes, monocytes, dendritic cells, Langerhans cells, keratinocytes, endothelial cells, astrocytes, fibroblasts, and oligodendrocytes).
  • T cells including T cytotoxic, T helper and Treg cells
  • the cells are T cells, which may be obtained as described herein and by methods known in the art.
  • the cell may be a human or non-human cell (including both prokaryotic and eukaryotic cells).
  • exemplary cells include, but are not limited to immune cells such as T cells, tumor infiltrating lymphocytes (TILs), NK cells, TCR- expressing cells, dendritic cells, and NK-T cells.
  • TILs tumor infiltrating lymphocytes
  • NK cells TCR-expressing cells
  • dendritic cells NK-T cells
  • NK-T cells eukaryotic cells
  • the T cells may be autologous, allogeneic, or heterologous.
  • the cells are T cells presenting a CAR.
  • the T cells may be CD4+ T cells or CD8+ T cells.
  • the T cell may be an in vivo T cell or an in vitro T cell.
  • the cells may be disposed in, or isolated from, any environment capable of maintaining the cells in a viable form, such as blood, tissue or any other sample obtained from a subject, cell culture media, tissue
  • the molecule comprising a CLL-1 binding molecule is a CAR.
  • the molecule may comprise a molecule, or fragment thereof, selected from the group consisting of CD28, OX-40, 4-1BB/CD137, CD2, CD7, CD27, CD30, CD40, Programmed Death- 1 (PD-1), inducible T cell co-stimulator (ICOS), lymphocyte function-associated antigen- 1 (LFA-1, CDl-la/CD18), CD3 gamma, CD3 delta, CD3 epsilon, CD3 zeta, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class 1 molecule, TNF receptor proteins, an Immunoglobulin protein, cytokine receptor, integrins, Signaling Lymphocytic Activation Molecules (SLAM proteins
  • the sample is then contacted with an antigen binding molecule that specifically binds a CLL-1 binding molecule and comprises a detectable label, under conditions that permit the formation of a binding complex comprising a cell present in the sample and the antigen binding molecule.
  • the antigen binding molecule is preferably an antigen binding molecule (or fragment thereof) disclosed herein, e.g ., in the sequence listing or the instant section of the disclosure. Any antigen binding molecule that specifically binds a CLL-1 binding molecule may be employed in the disclosed method. Multiple examples of suitable antigen binding molecules are provided herein, e.g. , those having one or more of the CDRs shown in Table C or D.
  • any detectable label may be employed in the method, as described herein, and suitable labels may be selected using a desired set of criteria.
  • detectable labels include fluorescent labels (e.g, fluorescein, rhodamine, tetramethylrhodamine, eosin, erythrosin, coumarin, methyl-coumarins, pyrene, Malachite green, stilbene, Lucifer Yellow, Cascade Blue, Texas Red, IAEDANS, EDANS, BODIPY FL, LC Red 640, Cy 5, Cy 5.5, LC Red 705, Oregon green, the Alexa-Fluor dyes (Alexa Fluor 350, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 647, Alexa Fluor 660, Alexa Fluor 680), Cascade Blue, Cas-cade Yellow and R-phycoerythrin
  • Suitable optical dyes including fluoro-phores, are described in Johnson, Molecular Probes Handbook:A Guide to Fluorescent Probes and Labeling Techniques. 11 th Edition. Life Technologies, (2010), hereby expressly incorporated by reference, radiolabels (e.g., isotope markers such as 3 H, U C, 14 C, 15 N, 18 F, 35 S, 64 CU, 90 Y, "Tc, U1 ln, 124 I, 125 I, 131 I), photochromic compounds, a Halo-tag, Atto dyes, Tracy dyes, proteinaceous fluorescent labels (e.g, proteinaceous fluorescent labels also include, but are not limited to, green fluorescent protein, including a Renilla, Ptilosarcus, or Aequorea species of GFP (Chalfie et al, (1994) Science 263:802-805), EGFP (Clon-tech Labs., Inc., Genbank Accession Number U55762), blue fluorescent protein (BFP, Quantum Biotechnologies
  • the label may be associated with the antigen binding molecule at any position in the molecule, although it is preferable to associate the label with the molecule at a position (or positions, if multiple labels are employed) at a point such that the binding properties of the molecule are not modified (unless such modified binding activity is desired).
  • Any antigen binding molecule that specifically binds a CLL-1 binding molecule (or fragment thereof) may be employed, such as those disclosed herein, e.g ., those having one or more of the CDRs shown in Table C or D.
  • the antigen binding molecule may be disposed on any surface, or no surface at all.
  • the antigen binding molecule may be present in a buffer and the buffer- antigen binding molecule may be contacted with the sample.
  • the antigen binding molecule may be associated with a surface. Suitable surfaces include agarose beads, magnetic beads such as DYNABEADS, or a plastic, glass or ceramic plate such as a welled plate, a bag such as a cell culture bag, etc.
  • the surface may itself be disposed in another structure, such as a column.
  • Conditions that permit the formation of a binding complex will be dependent on a variety of factors, however generally aqueous buffers at physiological pH and ionic strength, such as in phosphate-buffered saline (PBS), will favor formation of binding complexes and are preferred in the disclosed method.
  • PBS phosphate-buffered saline
  • the number of cells present in a binding complex in the sample is determined.
  • the specific method employed to determine the number of cells present in a binding complex will be dependent on the nature of the label selected. For example, FACS may be employed when a fluorescent label is selected; when an isotope label is selected mass spectrometry, NMR or other technique may be employed; magnetic-based cell sorting may be employed when a magnetic label is chosen; microscopy may also be employed.
  • the output of these detection methods may be in the form of a number of cells or the output may be of a form that allows the calculation of the number of cells based on the output.
  • the method comprises providing a sample known or suspected to comprise a molecule comprising a CLL-1 binding molecule.
  • the molecule comprising a CLL-1 binding molecule is a CAR.
  • the molecule may comprise a molecule, or fragment thereof, selected from the group consisting of CD28, OX-40, 4-1BB/CD137, CD2, CD7, CD27, CD30, CD40, Programmed Death- 1 (PD-1), inducible T cell co-stimulator (ICOS), lymphocyte function-associated antigen- 1 (LFA-1, CDl-la/CD18), CD3 gamma, CD3 delta, CD3 epsilon, CD3 zeta, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class 1 molecule, TNF receptor proteins, an Immunoglobulin protein, cytokine receptor, integrins, Signaling Lymphocytic Activation Molecules (SLAM proteins
  • An antigen binding molecule that specifically binds a CLL- 1 binding molecule and optionally comprises a detectable label is provided.
  • any detectable label may be employed in the method, as described herein, and suitable labels may be selected using a desired set of criteria.
  • detectable labels examples include fluorescent labels (e.g., fluorescein, rhodamine, tetramethylrhodamine, eosin, erythrosin, coumarin, methyl-coumarins, pyrene, Malachite green, stilbene, Lucifer Yellow, Cascade Blue, Texas Red, IAEDANS, EDANS, BOD IP Y FL, LC Red 640, Cy 5, Cy 5.5, LC Red 705, Oregon green, the Alexa-Fluor dyes (Alexa Fluor 350, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 647, Alexa Fluor 660, Alexa Fluor 680), Cascade Blue, Cas-cade Yellow and R-phycoerythrin (PE) (Molecular Probes), FITC, Rhodamine, and Texas Red (Pierce), Cy5, Cy5.5, Cy7
  • Radiolabels e.g ., isotope markers such as 3 H, U C, 14 C, 15 N, 18 F, 35 S, 64 CU, 90 Y, "TC, U1 ln, 124 1, 125 1, 131 I).
  • Photochromic compounds, a Halo-tag, Atto dyes, Tracy dyes, proteinaceous fluorescent labels e.g., proteinaceous fluorescent labels also include, but are not limited to, green fluorescent protein, including a Renilla, Ptilosarcus, or Aequorea species of GFP (Chalfie et al., (1994) Science 263:802-805), EGFP (Clon-tech Labs., Inc., Genbank Accession Number U55762), blue fluorescent protein (BFP, Quantum Biotechnologies, Inc; Stauber, (1998 ) Biotechniques 24:462-471; Heim et al, (1996) Curr. Biol.
  • green fluorescent protein including a Renilla, Ptilosarcus, or Aequorea species of GFP (Chalfie et al., (1994) Science 263:802-805), EGFP (Clon-tech Labs., Inc., Genbank Accession Number U55762), blue fluorescent protein (BFP, Quantum Biotechnologie
  • the label may be associated with the antigen binding molecule at any position in the molecule, although it is preferable to associate the label with the molecule at a position (or positions, if multiple labels are employed) at a point such that the binding properties of the molecule are not modified (unless such modified binding activity is desired).
  • Any antigen binding molecule that specifically binds anti-CLL-1 scFv (or fragment thereof) may be employed, such as those disclosed herein, e.g, those having one or more of the CDRs shown in Table C or D.
  • the antigen binding molecule may be disposed on any surface, or no surface at all.
  • the antigen binding molecule may be present in a buffer and the buffer- antigen binding molecule may be contacted with the sample.
  • the antigen binding molecule may be associated with a surface. Suitable surfaces include agarose beads, magnetic beads such as DYNABEADS, or a plastic, glass or ceramic plate such as a welled plate, a bag such as a cell culture bag, etc.
  • the surface may itself be disposed in another structure, such as a column.
  • binding complex Conditions that permit the formation of a binding complex will be dependent on a variety of factors, however generally aqueous buffers at physiological pH and ionic strength, such as in phosphate-buffered saline (PBS), will favor formation of binding complexes and are preferred in the disclosed method. Since the component parts of a binding complex may be disposed on surfaces as described herein, formed binding complexes may also be disposed on surfaces.
  • PBS phosphate-buffered saline
  • binding complexes may have formed, or a plurality of binding complexes comprising one or more antigen binding molecules bound to a molecule comprising a CLL-1 binding molecule (or one or more molecules comprising a CLL-1 binding molecule bound to an antigen binding molecule) may have formed. Unbound molecules comprising a CLL-1 binding molecule and/or unbound antigen binding molecules may also be present in the local environment of any formed binding complexes.
  • Any molecules not part of a binding complex are then separated from any formed binding complexes.
  • the method of the removal will depend on the structure and/or local environment of the binding complexes. For example, if the antigen binding molecule is disposed on a bead, plate or bag the unbound components of the reaction mixture may be washed away using a solution that leaves formed binding complexes intact. If a binding complex is disposed on a bead, the bead itself may be situated in a column or other structure and the same approach may be used.
  • the solution used to induce the formation of binding complexes may be used, for example, as a wash solution to remove unbound components. Any suitable buffer or solution that does not disrupt formed binding complexes may also be used. Typically, buffers having high salt concentrations, non-physiological pH, containing chaotropes or denaturants, are preferably avoided when performing this step of the method.
  • a formed binding complex is then separated into (a) a molecule comprising a
  • CLL-1 binding molecule and (b) an antigen binding molecule.
  • the separation may be achieved using standard methodologies known to those of skill in the art. For example, a solution of suitable pH and composition may be washed over the complexes. A solution that is commonly employed for this purpose is 0.1 M glycine HC1, pH 2.5-3.0, and this solution may be employed to achieve the separation.
  • the molecule comprising a CLL-1 binding molecule is of primary interest it may be collected; alternatively, if the antigen binding molecule is of primary interest it may be collected.
  • a molecule comprising a CLL-1 binding molecule it may sometimes be desirable to isolate a molecule comprising a CLL-1 binding molecule, as provided herein.
  • simply knowing whether a molecule comprising a CLL-1 binding molecule provided herein is present or absent from a sample is enough information.
  • the qualitative determination of the presence or absence of a molecule comprising a CLL-1 binding molecule of the instant disclosure may be useful in multiple applications.
  • a method of determining the presence or absence of a molecule comprising a CLL-1 binding molecule in a sample is provided.
  • the method comprises providing a sample known or suspected to comprise a molecule comprising a CLL-1 binding molecule.
  • the molecule comprising a CLL-1 binding molecule is a CAR.
  • the molecule may comprise a molecule, or fragment thereof, selected from the group consisting of CD28, OX-40, 4-1BB/CD137, CD2, CD7, CD27, CD30, CD40, Programmed Death- 1 (PD-1), inducible T cell co-stimulator (ICOS), lymphocyte function-associated antigen- 1 (LFA-1, CDl-la/CD18), CD3 gamma, CD3 delta, CD3 epsilon, CD3 zeta, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class 1 molecule, TNF receptor proteins, an Immunoglobulin protein, cytokine receptor, integrins, Signaling Lymphocytic Activation Molecules (SLAM proteins
  • An antigen binding molecule comprising a detectable label that specifically binds a CLL-1 binding molecule is provided.
  • Suitable labels may be selected using a desired set of criteria.
  • types of detectable labels include fluorescent labels (e.g., fluorescein, rhodamine, tetramethylrhodamine, eosin, erythrosin, coumarin, methyl- coumarins, pyrene, Malachite green, stilbene, Lucifer Yellow, Cascade Blue, Texas Red, IAEDANS, EDANS, BODIPY FL, LC Red 640, Cy 5, Cy 5.5, LC Red 705, Oregon green, the Alexa-Fluor dyes (Alexa Fluor 350, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 647, Alexa Fluor 660, Alexa Fluor 680), Cascade Blue
  • Suitable optical dyes including fluoro-phores, are described in Johnson, Molecular Probes Handbook: A Guide to Fluorescent Probes and Labeling Techniques. 11 th Edition. Life Technologies, (2010), hereby expressly incorporated by reference, radiolabels (e.g., isotope markers such as 3 H, U C, 14 C, 15 N, 18 F, 35 S, 64 CU, 90 Y, "Tc, U1 ln, 124 I, 125 I, 131 I), photochromic compounds, a Halo-tag, Atto dyes, Tracy dyes, proteinaceous fluorescent labels (e.g, proteinaceous fluorescent labels also include, but are not limited to, green fluorescent protein, including a Renilla, Ptilosarcus, or Aequorea species of GFP (Chalfie et ah, (1994) Science 263:802-805), EGFP (Clon-tech Labs., Inc., Genbank Accession Number U55762), blue fluorescent protein (BFP, Quantum Bio
  • the label may be associated with the antigen binding molecule at any position in the molecule, although it is preferable to associate the label with the molecule at a position (or positions, if multiple labels are employed) at a point such that the binding properties of the molecule are not modified (unless such modified binding activity is desired).
  • Any antigen binding molecule that specifically binds a CLL-1 binding molecule or fragment thereof) may be employed, such as those disclosed herein, e.g ., those having one or more of the CDRs shown in Table C or D.
  • the sample is contacted with the antigen binding molecule under conditions that permit the formation of a binding complex comprising a molecule comprising a CLL-1 binding molecule (which may be presented on a cell) present in the sample and the antigen binding molecule.
  • the antigen binding molecule may be disposed on any surface or no surface at all.
  • the antigen binding molecule may be present in a buffer and the buffer-antigen binding molecule may be contacted with the sample.
  • the antigen binding molecule may be associated with a surface. Suitable surfaces include agarose beads, magnetic beads such as DYNABEADS, or a plastic, glass or ceramic plate such as a welled plate, a bag such as a cell culture bag, etc.
  • the surface may itself be disposed in another structure, such as a column.
  • binding complex Conditions that permit the formation of a binding complex will be dependent on a variety of factors, however generally aqueous buffers at physiological pH and ionic strength, such as in phosphate-buffered saline (PBS), will favor formation of binding complexes and are preferred in the disclosed method. Since the component parts of a binding complex may be disposed on surfaces as described herein, formed binding complexes may also be disposed on surfaces.
  • PBS phosphate-buffered saline
  • binding complexes may have formed, or a plurality of binding complexes comprising one or more antigen binding molecules bound to a molecule comprising a CLL-1 binding molecule (or one or more molecules comprising a CLL-1 binding molecule bound to an antigen binding molecule) may have formed. Unbound molecules comprising a CLL-1 binding molecule and/or unbound antigen binding molecules may also be present in the local environment of any formed binding complexes.
  • Any molecules not part of a binding complex are then separated from any formed binding complexes.
  • the method of the removal will depend on the structure and/or local environment of the binding complexes. For example, if the antigen binding molecule is disposed on a bead, plate or bag the unbound components of the reaction mixture may be washed away using a solution that leaves formed binding complexes intact. If a binding complex is disposed on a bead, the bead itself may be situated in a column or other structure and the same approach may be used.
  • the solution used to induce the formation of binding complexes may be used, for example, as a wash solution to remove unbound components. Any suitable buffer or solution that does not disrupt formed binding complexes may also be used. Typically, buffers having high salt concentrations, non-physiological pH, containing chaotropes or denaturants, should be avoided when performing this step of the method.
  • a binding complex which will comprise a molecule comprising a CLL-1 binding molecule and an antigen binding molecule — is detected.
  • the specific method employed to detect the presence or absence of a binding complex will be dependent on the nature of the label selected. For example, FACS may be employed when a fluorescent label is selected; when an isotope label is selected mass spectrometry, NMR or other technique may be employed; magnetic-based cell sorting may be employed when a magnetic label is chosen; microscopy may also be employed.
  • the end result of the method is a qualitative assessment of the presence or absence of the antigen binding molecule comprising the detectable label, and thus, the presence or absence of its binding partner, the molecule comprising a CLL-1 binding molecule.
  • the molecule comprising a
  • the CLL-1 binding molecule may be disposed in any environment.
  • the molecule comprising a CLL-1 binding molecule is expressed on the surface of a cell.
  • the cell may be of any type, and may be human or non-human (e.g ., mouse, rate, rabbit, hamster, etc).
  • the cell is an immune cell.
  • An immune cell of the method may be any type of immune cell (e.g., B lymphocytes, monocytes, dendritic cells, Langerhans cells, keratinocytes, endothelial cells, astrocytes, fibroblasts, and oligodendrocytes).
  • T cells including T cytotoxic, T helper and Treg cells are especially preferred.
  • the cells are T cells, which may be obtained as described herein and by methods known in the art. Any type of immune cell may be employed in this embodiment of the disclosed method, and the cell may be a human or non-human cell (including both prokaryotic and eukaryotic cells). Exemplary cells include, but are not limited to immune cells such as T cells, tumor infiltrating lymphocytes (TILs), NK cells, TCR- expressing cells, dendritic cells, and NK-T cells. The T cells may be autologous, allogeneic, or heterologous. In additional embodiments, the cells are T cells presenting a CAR. The T cells may be CD4+ T cells or CD8+ T cells. When a T cell is employed in the disclosed methods, the T cell may be an in vivo T cell or an in vitro T cell.
  • the cell may be disposed in, or isolated from, any environment capable of maintaining the cell in a viable form, such as blood, tissue or any other sample obtained from a subject, cell culture media, tissue grown ex vivo , a suitable buffer, etc.
  • a molecule of interest is present in a sample in lower-than-desired levels. For example, when a cell is transfected with a foreign gene expression levels of the protein(s) encoded by the foreign gene are sometimes low. The same may be true for molecules secreted from a cell; such molecules are often present in low quantities (but may still be detected using the methods provided herein, if the molecule comprises a CLL-1 binding molecule.
  • One solution to the problem of low expression levels is to increase the concentration of the molecule of interest, which may be free in solution, or expressed on the surface of a cell. The concentration of intracellularly-expressed molecules of interest may also be enhanced, however the cells must first be lysed to release the molecule. To address this problem, a method of increasing the concentration of cells presenting a molecule comprising a CLL-1 binding molecule is provided.
  • the method comprises providing a sample comprising cells known or suspected to present a molecule comprising a CLL-1 binding molecule.
  • the molecule comprising the sequence a CLL-1 binding molecule is a CAR.
  • the molecule may comprise a molecule, or fragment thereof, selected from the group consisting of CD28, OX-40, 4-1BB/CD137, CD2, CD7, CD27, CD30, CD40, Programmed Death- 1 (PD-1), inducible T cell co-stimulator (ICOS), lymphocyte function-associated antigen-1 (LFA-1, CDl-la/CD18), CD3 gamma, CD3 delta, CD3 epsilon, CD3 zeta, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class 1 molecule, TNF receptor proteins, an Immunoglobulin protein, cytokine receptor, integrins, Signaling Lymphocytic Activation Molecules (SLAM), Fc gamma receptor, MHC class 1
  • An antigen binding molecule that specifically binds a CLL-1 binding molecule, and optionally comprises a detectable label is provided.
  • any detectable label may be employed in the method, as described herein, and suitable labels may be selected using a desired set of criteria.
  • detectable labels examples include fluorescent labels (e.g ., fluorescein, rhodamine, tetramethylrhodamine, eosin, erythrosin, coumarin, methyl-coumarins, pyrene, Malachite green, stilbene, Lucifer Yellow, Cascade Blue, Texas Red, IAEDANS, EDANS, BOD IP Y FL, LC Red 640, Cy 5, Cy 5.5, LC Red 705, Oregon green, the Alexa-Fluor dyes (Alexa Fluor 350, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 647, Alexa Fluor 660, Alexa Fluor 680), Cascade Blue, Cas-cade Yellow and R-phycoerythrin (PE) (Molecular Probes), FITC, Rhodamine, and Texas Red (Pierce), Cy5, Cy5.5,
  • Suitable optical dyes including fluoro-phores, are described in Johnson, Molecular Probes HandbooLA Guide to Fluorescent Probes and Labeling Techniques. 11 th Edition. Life Technologies, (2010), hereby expressly incorporated by reference, radiolabels (e.g., isotope markers such as 3 H, U C, 14 C, 15 N, 18 F, 35 S, 64 CU, 90 Y, "TC, U1 ln, 124 1, 125 1, 131 I), photochromic compounds, a Halo-tag, Atto dyes, Tracy dyes, proteinaceous fluorescent labels (e.g, proteinaceous fluorescent labels also include, but are not limited to, green fluorescent protein, including a Renilla, Ptilosarcus, or Aequorea species of GFP (Chalfie et al., (1994) Science 263:802-805), EGFP (Clon-tech Labs., Inc., Genbank Accession Number U55762), blue fluorescent protein (BFP, Quantum Biotechnologies, Inc
  • the label may be associated with the antigen binding molecule at any position in the molecule, although it is preferable to associate the label with the molecule at a position (or positions, if multiple labels are employed) at a point such that the binding properties of the molecule are not modified (unless such modified binding activity is desired).
  • Any antigen binding molecule that specifically binds a CLL-1 binding molecule (or fragment thereof) may be employed, such as those disclosed herein, e.g. , those having one or more of the CDRs shown in Table C or D.
  • the antigen binding molecule may be disposed on any surface, or no surface at all.
  • the antigen binding molecule may be present in a buffer and the buffer- antigen binding molecule may be contacted with the sample.
  • the antigen binding molecule may be associated with a surface. Suitable surfaces include agarose beads, magnetic beads such as DYNABEADS, or a plastic, glass or ceramic plate such as a welled plate, a bag such as a cell culture bag, etc.
  • the surface may itself be disposed in another structure, such as a column.
  • a cell presenting a molecule comprising a CLL-1 binding molecule may be of any type, and may be human or non-human (e.g, mouse, rate, rabbit, hamster, etc).
  • the cell is an immune cell.
  • An immune cell of the method may be any type of immune cell (e.g, B lymphocytes, monocytes, dendritic cells, Langerhans cells, keratinocytes, endothelial cells, astrocytes, fibroblasts, and oligodendrocytes).
  • T cells including T cytotoxic, T helper and Treg cells
  • the cells are T cells, which may be obtained as described herein and by methods known in the art.
  • the cell may be a human or non-human cell (including both prokaryotic and eukaryotic cells).
  • exemplary cells include, but are not limited to immune cells such as T cells, tumor infiltrating lymphocytes (TILs), NK cells, TCR-expressing cells, dendritic cells, and NK-T cells.
  • TILs tumor infiltrating lymphocytes
  • NK cells TCR-expressing cells
  • dendritic cells NK-T cells.
  • NK-T cells tumor infiltrating lymphocytes
  • the T cells may be autologous, allogeneic, or heterologous.
  • the cells are T cells presenting a CAR.
  • the T cells may be CD4+ T cells or CD8+ T cells.
  • the T cell may be an in vivo T cell or an in vitro T cell.
  • the cells may be disposed in, or isolated from, any environment capable of maintaining the cells in a viable form, such as blood, tissue or any other sample obtained from a subject, cell culture media
  • the sample comprising cells is contacted with the antigen binding molecule, under conditions that permit the formation of a binding complex comprising a molecule comprising a CLL-1 binding molecule and the antigen binding molecule.
  • Conditions that permit the formation of a binding complex will be dependent on a variety of factors, however generally aqueous buffers at physiological pH and ionic strength, such as in phosphate- buffered saline (PBS), will favor formation of binding complexes and are preferred in the disclosed method. Since the component parts of a binding complex may be disposed on surfaces as described herein, formed binding complexes may also be disposed on surfaces.
  • binding complexes may have formed, or a plurality of binding complexes comprising one or more antigen binding molecules bound to a molecule comprising a CLL-1 binding molecule (or one or more molecules comprising a CLL-1 binding molecule bound to an antigen binding molecule) may have formed. Unbound molecules comprising a CLL-1 binding molecule and/or unbound antigen binding molecules may also be present in the local environment of any formed binding complexes.
  • Any molecules or cells not part of a binding complex are then separated from any formed binding complexes.
  • the method of the removal will depend on the structure and/or local environment of the binding complexes. For example, if the antigen binding molecule is disposed on a bead, plate or bag the unbound components of the reaction mixture may be washed away using a solution that leaves formed binding complexes intact. If a binding complex is disposed on a bead, the bead itself may be situated in a column or other structure and the same approach may be used.
  • the solution used to induce the formation of binding complexes may be used, for example, as a wash solution to remove unbound components. Any suitable buffer or solution that does not disrupt formed binding complexes may also be used. Typically, buffers having high salt concentrations, non-physiological pH, containing chaotropes or denaturants, should be avoided when performing this step of the method.
  • a population of cells presenting a molecule comprising a CLL-1 binding molecule will be present. If a detectable label was employed, the concentration of the cells may be easily determined, consistent with the nature of the label. Cells not expressing the molecule comprising a CLL-1 binding molecule will be absent, and thus the population (or concentration) of cells presenting a molecule comprising a CLL-1 binding molecule will be increased compared to the levels prior to performing the method.
  • the above steps may be repeated a desired number of times.
  • a desired number of times may also be zero, if the desired concentration of cells is already present.
  • a subject When a subject has an immune cell-mediated condition, it may be of significant importance that the condition be controlled in a timely fashion so as to prevent harm to the subject. For example, when a subject has an autoimmune reaction it may be desirable to suppress an immune cell-mediated response by depleting a population of immune cells, in an effort to prevent harm. In another example, a subject receiving immunotherapy may react too strongly to the therapy and be at risk of harm; depleting the population of immune cells administered to the subject may be an effective approach to mitigating the subject’s reaction to the immunotherapy.
  • a method of depleting a population of immune cells presenting a molecule comprising a CLL-1 binding molecule is provided.
  • An antigen binding molecule that specifically recognizes an anti-CLL-1 scFv, e.g, those having one or more of the CDRs shown in Table C or D, may be employed in the method.
  • the method comprises providing a population of immune cells to be depleted, wherein the cells are known or suspected to be expressing a molecule comprising a CLL-1 binding molecule.
  • the molecule comprising a CLL-1 binding molecule is a CAR.
  • the molecule may comprise a molecule, or fragment thereof, selected from the group consisting of CD28, OX-40, 4-1BB/CD137, CD2, CD7, CD27, CD30, CD40, Programmed Death- 1 (PD-1), inducible T cell co-stimulator (ICOS), lymphocyte function-associated antigen- 1 (LFA-1, CDl-la/CD18), CD3 gamma, CD3 delta, CD3 epsilon, CD3 zeta, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class 1 molecule, TNF receptor proteins, an Immunoglobulin protein, cytokine receptor, integrins, Signaling Lymphocytic Activation Molecules (SLAM proteins
  • An immune cell expressing a molecule comprising a CLL-1 binding molecule sequence may be of any type, and may be human or non-human (e.g ., mouse, rate, rabbit, hamster, etc).
  • An immune cell of the method may be any type of immune cell (e.g., B lymphocytes, monocytes, dendritic cells, Langerhans cells, keratinocytes, endothelial cells, astrocytes, fibroblasts, and oligodendrocytes).
  • T cells including T cytotoxic, T helper and Treg cells
  • the cells are T cells, which may be obtained as described herein and by methods known in the art.
  • the cell may be a human or non-human cell (including both prokaryotic and eukaryotic cells).
  • exemplary cells include, but are not limited to immune cells such as T cells, tumor infiltrating lymphocytes (TILs), NK cells, TCR-expressing cells, dendritic cells, and NK-T cells.
  • TILs tumor infiltrating lymphocytes
  • NK cells TCR-expressing cells
  • dendritic cells and NK-T cells.
  • the T cells may be autologous, allogeneic, or heterologous.
  • the cells are T cells presenting a CAR.
  • the T cells may be CD4+ T cells or CD8+ T cells.
  • the T cell may be an in vivo T cell or an in vitro T cell.
  • the cells may be disposed in, or isolated from, any environment capable of maintaining the cells in a viable form, such as blood, tissue or any other sample obtained from a subject, cell culture media, tissue grown ex vivo, a suitable buffer, etc.
  • a viable form such as blood, tissue or any other sample obtained from a subject, cell culture media, tissue grown ex vivo, a suitable buffer, etc.
  • the population of immune cells are disposed in a subject, and more preferably a human subject.
  • the immune cells are contacted with an antigen binding molecule that specifically binds to (a) the molecule comprising a CLL-1 binding molecule, and (b) an activating molecule expressed on the surface of an immune cell, under conditions that permit the formation of a ternary binding complex comprising the molecule comprising a CLL-1 binding molecule, the activating molecule and the antigen binding molecule.
  • the immune cell expressing the activating molecule expresses a molecule comprising a CLL-1 binding molecule.
  • the immune cell expressing the activating molecule does not express a molecule comprising a CLL-1 binding molecule.
  • the antigen binding molecule may be disposed on any surface, or no surface at all.
  • the antigen binding molecule (which may also comprise the population of immune cells to be depleted and/or may be present in a buffer) and the buffer-antigen binding molecule may be contacted with the sample.
  • the antigen binding molecule may be associated with a surface. Suitable surfaces include agarose beads, magnetic beads such as DYNABEADS, or a plastic, glass or ceramic plate such as a welled plate, a bag such as a cell culture bag, etc. The surface may itself be disposed in another structure, such as a column.
  • the immune cells are contacted with the antigen binding molecule, under conditions that permit the formation of a ternary binding complex comprising a molecule comprising a CLL-1 binding molecule sequence, the antigen binding molecule and an activating molecule expressed on the surface of an immune cell not expressing the molecule comprising a CLL-1 binding molecule.
  • Conditions that permit the formation of a binding complex will be dependent on a variety of factors, however generally aqueous buffers at physiological pH and ionic strength, such as in phosphate-buffered saline (PBS), will favor formation of binding complexes and are preferred in the disclosed method. Since the component parts of a binding complex may be disposed on surfaces as described herein, formed binding complexes may also be disposed on surfaces.
  • the contacting is performed by administering the antigen binding molecule directly to a subject.
  • the subject will already have a population of cells to be depleted, wherein the cells express a molecule comprising a CLL-1 binding molecule sequence.
  • these cells, as well as cells presenting an activating molecule will be present in the subject prior to the administration of the antigen binding molecule to the subject.
  • the human blood, lymph and tissue environment will permit the formation of ternary binding complexes.
  • the binding of the antigen binding molecule with the molecule comprising a CLL-1 binding molecule sequence serves to “tag” those cells presenting the molecule comprising a CLL-1 binding molecule ⁇ i.e., the cells to be depleted).
  • This binding event may or may not lead to depletion on its own.
  • this binding event brings both cells (i.e., the cell expressing the molecule comprising a CLL-1 binding molecule, and the cell expressing the activating molecule) together into proximity.
  • the physiological result of the binding event is the killing of the cell expressing the molecule comprising a CLL-1 binding molecule.
  • the instant disclosure comprises a number of nucleic acid and polypeptide sequences.
  • Table E correlates each sequence with its appropriate description and SEQ ID NO.
  • Monoclonal antibodies were generated through immunization of rabbits using an anti-CLL-1 scFv, conjugated to Fc as immunogen. Titer was determined via screening polyclonal sera by ELISA. A secondary screen was performed using CAR T cells assayed via flow cytometry. Once titer was achieved, the immunized rabbits were sacrificed and monoclonals were derived using standard hybridoma generation and subcloning techniques. The final screening of the hybridoma subclones was accomplished via additional rounds of flow cytometry of proliferating CAR T cells. The sequences of the final subclones selected were determined by standard Sanger sequencing of the hybridomas subclones.
  • PBMCs were isolated from healthy donor leukopaks (HemacareTM) using ficoll-paque density centrifugation per manufacturer’s instructions. PBMCs were stimulated using OKT3 (50ng/ml, Miltenyi BiotecTM) in OpTmizer media + OpTmizer supplements + IL-2 (300IU/ml, Proleukin®, Prometheus® Therapeutics and Diagnostics). Two days after stimulation, CAR T cells presenting the anti-CLL-1 scFv were generated through viral transduction of these activated primary human T cells. Transduction was performed using lentivirus to express the CAR.
  • Histograms in Figure 1 show antibody binding to CAR-expressing T cells demonstrating that KIP-10 clonal supernatants bind anti-CLL-1 CAR-expressing T cells, but not two control CAR-expressing T cells (CAR 2 and CAR3).
  • the antigen binding molecules disclosed herein are anti -idiotypic antigen binding molecules, and recognize an epitope on a CLL-1 binding molecule.
  • An antigen binding molecule e.g ., an antibody
  • An antigen binding molecule may thus be used to purify a molecule, such as a CLL-1 binding molecule, macromolecule, polymer, cell, material, etc., displaying an epitope that is recognized by the antigen binding molecules disclosed herein.
  • an antigen binding molecule disclosed herein e.g., a fragment of an antigen binding molecule.
  • Clones 15-2, 63-2, 103-2, 147-1, 148-4, 160-1/or and 180-2 and fragments thereof) may be attached to beads, attached to or associated with a resin, which may be disposed in a column or other structure.
  • a sample comprising a molecule comprising all or a fragment of anti- CLL-1 scFv may then be contacted with the beads, resin, etc to which the antigen binding molecule was attached or with which an antigen binding molecule was associated. This allows the formation of an association or binding complex comprising the antigen binding molecule and the molecule comprising all or a fragment of a CLL-1 binding molecule.
  • the beads or resin may then be washed with a suitable solution, such as a buffer solution (e.g, PBS, HEPES, MOPS, Tris, Tricine, etc) having a pH selected to maintain the stability of the molecule comprising all or a fragment of a CLL-1 binding molecule.
  • a buffer solution e.g, PBS, HEPES, MOPS, Tris, Tricine, etc
  • the washing may remove unwanted and unbound components of the sample.
  • the molecule comprising all or a fragment of a CLL-1 binding molecule may then be eluted from the antigen binding molecules using an elution buffer and conditions selected to disrupt any association or binding complexes formed.
  • elution buffers include 0.1M glycine, pH 2.5-3.0, and 0.1M citric acid, pH 3.0, 50-100mM triethylamine or triethanolamine, pH 11.5, 3.5-4.0M magnesium chloride, pH 7.0 in lOmM Tris, 2-6M guanidine, and 2-8M urea.
  • eluted molecules, cells and moieties of interest comprising all or a fragment of a CLL-1 binding molecule is collected, and purity may be subsequently checked by running a sample on an SDS polyacrylamide gel.
  • an antigen binding molecule may be disposed in solution with any molecular entity displaying the epitope, and purified from a mixed population of molecules, cells, etc. and eluted from the beads, resin, or free antibody by washing with 300-500 mM sodium chloride or lowering the pH and neutralizing with 1 M Tris, for proteins, or phosphate buffer. Subsequently, dialysis may be used to return materials to desired buffer conditions.
  • cells displaying a molecule comprising all or a fragment of a CLL-1 binding molecule may be incubated with magnetic beads (e.g ., DYNABEADS) with which an antigen binding molecule disclosed herein has been associated.
  • magnetic beads e.g ., DYNABEADS
  • the incubation is performed under conditions that both allow for the formation of binding complexes/associations, such as under physiological conditions, in the presence of a media selected for this purpose (e.g., RPMI-1640).
  • the beads are then separated from cells not displaying a molecule comprising a CLL-1 binding molecule or fragment thereof.
  • the beads may be washed with media, such as RPMI-1640 supplemented with 10% FBS, in the presence of a magnet.
  • Selected cells i.e., those presenting molecules that comprise a CLL-1 binding molecule may then be separated from the beads: First, selected cells are grown out in media. After growing out cells for 48 hours, the magnetic beads may be separated from cells in solution and discarded, leaving a pure population of cells expressing desired molecule.
  • the beads are not magnetic, and in this embodiment the above steps may also be followed and adapted to maintain cell integrity, but also to allow separation of bead-bound cells from non-bead bound cells.
  • an antigen binding molecule disclosed herein may be His-tagged (i.e., labeled with a short polyhistidine sequence), thereby facilitating the separation of cells using a resin comprising a transition metal ion such as Ni 2+ , Co 2+ , Cu 2+ or Zn 2+ , which are immobilized on the resin.
  • the antigen binding molecules may then be incubated with cells known or suspected to be expressing a CLL-1 binding molecule under conditions suitable for the formation of complexes comprising the cells and the antigen binding molecules.
  • the cells are contacted with the resin, which may be disposed in a solid structure such as a welled plate, column or other structure.
  • the antigen binding molecule-cell complexes may then be separated from one another by washing with imidazole, which will be of a higher concentration than any imidazole included in any solutions used in the formation of the binding complexes.
  • Eluted cells may then be spun down, washed in RPMI or other suitable media, and then resuspended in media.
  • Activating CAR-positive T cells Using Antibodies to an Anti-CLL-1 CAR also provided is a method of activating CAR-positive T cells presenting a molecule comprising a specific idiotope recognized by a specific antigen binding molecule (e.g ., an antigen binding molecule that comprises a CLL-1 binding molecule, such as those disclosed herein: Clone 15-2, 63-2, 103-2, 147-1, 148-4, 160-1 and 180-2, and fragments thereof).
  • This method may be adapted for any antibody recognizing a protein of interest on a T-cell containing an activation domain, such as a chimeric antigen receptor (CAR) comprising a CLL-1 binding molecule.
  • Activation may be achieved using plate-bound, bead- bound, polymer-bound, or other form of the antibody that specifically recognizes an extracellular component of the CAR or similar molecule.
  • the method may be performed as follows: first, a 12- well tissue culture treated plate is coated with 1.5 pg/mL of a CLL-1 binding molecule antigen binding molecule disclosed herein, which has been diluted in HBSS or other phosphate buffer, and placed in an incubator at 37 C for 2 hours. Next, the plate is washed three times with HBSS or other phosphate buffer having a suitable pH, ionic strength, etc. Continuing, CAR positive T-cells in OpTmizer media (with supplements) or RPMI-1640 media with 10% FBS are added to the tissue culture treated plate. The cells are then grown at 37 C with 5% CO2. [0411] After 2 days, the cells are examined to determine any increase in the percent
  • CAR-positive cells This determination may be made by identifying any increase in the expression of any cell-surface and/or internal markers, including, but not limited to 4- IBB, CD69, CD25, PD-1, and Ki-67.
  • Chemical Computing Group may be used to generate alignments between the rabbit antibody Clones 15-2, 63-2, 103-2, 147-1, 148-4, 160-1 and 180-2 and pairs of variable light and heavy chains, VL and VH, respectively from two databases:
  • the Abysis human database a database of about 2000 known human VL/VH sequence pairs from IMGT-LigM DB;
  • a human germline database a database of germline sequences.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des molécules de liaison à l'antigène isolées qui se lient de manière spécifique à une molécule de liaison à CLL-1. Les molécules de liaison à l'antigène peuvent être utilisées dans les procédés fournis par la présente invention.
EP20817103.3A 2019-10-23 2020-10-23 Molécules de liaison à l'antigène anti-idiotypiques et procédés d'utilisation associés Pending EP4048696A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962924843P 2019-10-23 2019-10-23
PCT/US2020/057072 WO2021081330A1 (fr) 2019-10-23 2020-10-23 Molécules de liaison à l'antigène anti-idiotypiques et procédés d'utilisation associés

Publications (1)

Publication Number Publication Date
EP4048696A1 true EP4048696A1 (fr) 2022-08-31

Family

ID=73654875

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20817103.3A Pending EP4048696A1 (fr) 2019-10-23 2020-10-23 Molécules de liaison à l'antigène anti-idiotypiques et procédés d'utilisation associés

Country Status (3)

Country Link
US (1) US20220396628A1 (fr)
EP (1) EP4048696A1 (fr)
WO (1) WO2021081330A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4401835A1 (fr) * 2021-09-13 2024-07-24 The Board Of Regents Of The University Of Texas System Protéines de liaison à l'antigène trem2 et leurs utilisations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
CA2089661C (fr) 1990-08-29 2007-04-03 Nils Lonberg Animaux transgeniques non humains capables de produire des anticorps heterologues
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
WO2009051974A1 (fr) * 2007-10-17 2009-04-23 Nuvelo, Inc. Anticorps anti-cll-1
DK3214091T3 (en) 2010-12-09 2019-01-07 Univ Pennsylvania USE OF CHEMICAL ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF CANCER
US9163090B2 (en) * 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
BR112017004802A2 (pt) * 2014-09-12 2017-12-12 Genentech Inc anticorpos anti-cll-1 e imunoconjugados
TW201718647A (zh) * 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
CA3004743A1 (fr) * 2015-11-24 2017-06-01 Cellerant Therapeutics, Inc. Anticorps anti-cll-1 humanises

Also Published As

Publication number Publication date
WO2021081330A1 (fr) 2021-04-29
US20220396628A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
US11384155B2 (en) Antigen binding molecules specific for an anti-CD19 scFv
US20200377609A1 (en) Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule
AU2020210684B2 (en) Antigen binding molecules and methods of use thereof
US11834654B2 (en) Antigen binding molecules and methods of use thereof
US20220396628A1 (en) Anti-idiotypic antigen binding molecules and methods of use thereof
US20240343820A1 (en) Antigen binding molecules and methods of use
TW202436355A (zh) 抗原結合分子及使用方法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220518

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080030

Country of ref document: HK